

**CURRICULUM VITAE**  
**Herbert D. Aronow, M.D., M.P.H.**

**PERSONAL INFORMATION**

Date of Birth	March 30, 1967
Place of Birth	Abington, PA
Address	26 Miss Fry, East Greenwich, RI 02818
Phone	734-646-1730
Email	<a href="mailto:herbert_aronow@brown.edu">herbert_aronow@brown.edu</a>

**EDUCATION**

1985 - 1989	Bachelor of Arts, Psychology <i>Cum Laude</i>	University of Michigan
1989 - 1994	Doctor of Medicine	University of Michigan
1992 - 1993	Non-degree program	Tel Aviv University Graduate Middle Eastern Studies
1997 - 1998	Masters in Public Health	University of Michigan

**POSTGRADUATE TRAINING**

1994 – 1997	Internal Medicine	University of Michigan 3110 Taubman Center 1500 E. Medical Center Drive Ann Arbor, MI 48109
1998 – 2001	Cardiovascular Medicine	Cleveland Clinic Foundation Dept of Cardiovascular Medicine 9500 Euclid Ave Cleveland, OH 44195
2001 – 2003	Interventional Cardiology	Cleveland Clinic Foundation Dept of Cardiovascular Medicine 9500 Euclid Ave Cleveland, OH 44195

**POSTGRADUATE HONORS AND AWARDS**

1997	Galens Medical Society Bronze Beeper Award for Medical Student Teaching
1999	Cleveland Clinic Foundation Joseph Cash Memorial Award for Original Investigation in Health Outcomes

- 1999 Bristol-Myers Squibb Cardiology Fellows Abstract Award
- 2000 AstraZeneca Cardiovascular Young Investigators' Forum Finalist
- 2001 American College of Cardiology/Bristol-Myers Squibb Affiliate Travel Award
- 2001 Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Clinical Fellow Research Award
- 2002 Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award Finalist
- 2009 CRT Emerging Young Leadership Award for Interventional Cardiology
- 2010 St. Joseph Mercy Hospital Reichert Award for Resident Research Mentorship
- 2011 Subspecialty Teacher of the Year Award Finalist. St. Joseph Mercy Hospital, Internal Medicine Residency
- 2011 1<sup>st</sup> Place, BMEidea (Biomedical Engineering Innovation, Design and Entrepreneurship Award (Clinical mentor for University of Michigan BME 599 student team). New York, NY
- 2013 – 2015 Fellow, SCAI-ACC-CRF Emerging Leader Mentorship (ELM) Program
- 2013 Washtenaw County Chapter American Heart Association, Young Investigator Award for Excellence
- 2014 W.L. Gore & Associates Pioneer in Performance for North America: Dedication to Analysis of Clinical Outcomes
- 2017 Certificate of Exemplary Teaching in BIOL 3662 IMS III: Cardiovascular, Warren Alpert Medical School of Brown University
- 2018 Inductee, International Andreas Gruentzig Society.
- 2018 The Miriam Hospital Physician C.A.R.E. (Compassion, Accountability, Respect, Excellence) Award for Enhancing Patient Experience
- 2019 The Miriam Hospital Physician C.A.R.E. (Compassion, Accountability, Respect, Excellence) Award for Enhancing Patient Experience
- 2019 Certificate of Exemplary Teaching in BIOL 3662 IMS III: Cardiovascular, Warren Alpert Medical School of Brown University

### **MILITARY SERVICE**

N/A

## **PROFESSIONAL LICENSES AND BOARD CERTIFICATION**

### Medical Licensure

<u>State</u>	<u>License #</u>	<u>Issue Date</u>	<u>Expiration Date</u>
Ohio (training)	57.002590	8/00	6/03
Pennsylvania	MD422036	6/03	12/06
Michigan	5315102784	7/96	1/21
Rhode Island	MD15047	5/15	6/22

### Board Certification

1997	Internal Medicine, American Board of Internal Medicine
2002, 2012	Cardiovascular Disease, American Board of Internal Medicine
2003, 2013	Interventional Cardiology, American Board of Internal Medicine
2016	American Board of Vascular Medicine – Vascular Medicine
2016	American Board of Vascular Medicine – Endovascular Medicine

## **ACADEMIC APPOINTMENTS**

2003 - 2006	Assistant Professor, Cardiovascular Medicine Division, University of Pennsylvania School of Medicine
2008 - present	Adjunct Clinical Instructor, Division of Cardiovascular Medicine, University of Michigan Medical School
2015 - present	Candidate interviewer. Brown Cardiovascular Medicine Fellowship
2015 - present	Candidate interviewer. Brown Interventional Cardiology Fellowship
2015 - present	Candidate interviewer. Brown Vascular and Endovascular Medicine Fellowship
2015 - present	Candidate interviewer. Brown Structural Heart Disease Fellowship
2015 – 2019	Assistant Professor, Cardiovascular Medicine, Warren Alpert Medical School of Brown University

2019 - present Associate Professor, Cardiovascular Medicine, Warren Alpert Medical School of Brown University

### **HOSPITAL APPOINTMENTS**

1996 – 1997 Vice President, House Officers Association, University of Michigan

1997 – 1998 Attending Physician, Medical Teaching Service, Department of Internal Medicine, St. Joseph Mercy Hospital, Ann Arbor, MI

2003 – 2005 **Director**, Peripheral Vascular Intervention, Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Philadelphia, PA

2003 – 2005 **Director**, Cardiac Catheterization Lab, Philadelphia Veterans Administration Medical Center, Philadelphia, PA

2003 – 2005 **Co-Director**, Outpatient Vascular Center, Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Philadelphia, PA

2005 – 2015 Attending Physician, Department of Internal Medicine, St. Joseph Mercy Hospital, Ann Arbor, MI

2005 – 2015 Attending Physician, Department of Internal Medicine, St. Mary Mercy Hospital, Livonia, MI

2005 – 2015 Attending Physician, Department of Internal Medicine, Allegiance Hospital, Jackson, MI

2005 – 2015 Clinical Scholar/Clinical Investigator, Michigan Heart and Vascular Institute, Ann Arbor, MI

2005 – 2015 **Director**, Peripheral Vascular Intervention & Peripheral Vascular Catheterization Laboratory, St. Joseph Mercy Hospital, Michigan Heart Division, Ann Arbor, MI

2005 – 2015 Member, Michigan Heart Research Executive Committee

2005 – 2015 Member, Vascular Steering Committee, Michigan Heart & Vascular Institute, St. Joseph Mercy Hospital

2005 – 2015 Member, Peripheral Vascular Clinical Management Committee, Michigan Heart & Vascular Institute, St. Joseph Mercy Hospital

2005 – 2014 Member, Research Committee, St. Joseph Mercy Hospital

2006 – 2015 Member, Stroke Clinical Practice Team, St. Joseph Mercy Hospital

2007 – 2015      **Director**, Michigan Heart Comprehensive Vascular Program

2007 – 2015      Member, Peripheral Intervention Committee, Allegiance Hospital

2007 – 2015      Member, Interdisciplinary Vascular Council, St. Mary Mercy Hospital

2008 – 2010      Board Member, Michigan Heart & Vascular Institute, St. Joseph Mercy Hospital

2008 – 2011      **Chair**, Vascular Steering Committee, Michigan Heart & Vascular Institute, St. Joseph Mercy Hospital

2010 – 2013      Member, Cardiovascular Quality Committee, St. Joseph Mercy Hospital

2010 – 2013      Member, Cardiovascular Operations Committee, St. Joseph Mercy Hospital

2012              **Assistant Director**, Cardiac Catheterization Laboratory, St. Joseph Mercy Hospital, Ann Arbor, MI

2013              **Interim Director**, Cardiac Catheterization Laboratory, St. Joseph Mercy Hospital, Ann Arbor, MI

2015 – 2016      Member, Cardiovascular Value Analysis Committee, Lifespan. Providence, RI

2015 – 2016      Member, Access Steering Committee, Lifespan Cardiovascular Institute, Providence, RI

2015 – 2016      **Co-Chair**, Cardiac Catheterization and Electrophysiology Lab Workflow Optimization Committee, Lifespan Cardiovascular Institute, Providence, RI

2015 – present    **Director**, Interventional Cardiology, Lifespan Cardiovascular Institute. Providence, RI

2015 – present    **Director**, Cardiac Catheterization Laboratories, Rhode Island and The Miriam Hospitals. Providence, RI

2015 – present    Member, Senior Operations Group, Lifespan Cardiovascular Institute, Providence, RI

2015 – 2016      Member, ICCU/CCU Collaborative Practice Committee, Lifespan Cardiovascular Institute, Providence, RI

2015 – present    Member, Quality Steering Committee, Lifespan Cardiovascular Institute, Providence, RI

2015 – present    Member, Lifespan Radiation Safety Committee, Providence, RI

2015 – 2016	Member, Brown University Search Committee, Chair of Anesthesiology
2015 – 2016	Member, Lifespan Search Committee, Cardiac Surgery
2016 – 2017	Member, Lifespan CVI APP Task Force
2016 – 2017	Member, Lifespan Physician Group Transition Working Group
2017 – present	<b>Co-Chair</b> , Quality Steering Committee, Lifespan Cardiovascular Institute, Providence, RI.
2017 – 2018	Physician Liaison, Value Based Care for Cardiac Patients. Lifespan Physician Group. Providence, RI.
2018 – 2021	<b>Trustee</b> , Lifespan Physician Group
2018 – present	Member, Lifespan Physician Group Academic Committee

### **REGIONAL APPOINTMENTS**

2005 – 2015	Member, Writing Committee, Blue Cross Blue Shield of Michigan Percutaneous Coronary Intervention (BMC2 PCI) Registry
2006 – 2015	Member, Writing Committee, Blue Cross Blue Shield of Michigan Peripheral Vascular Intervention/Vascular Interventions Collaborative (BMC2 PVI/VIC) Registry
2007	Member, Michigan Department of Community Health (MDCH), Cardiac Catheterization Certificate of Need (CON) Standards Advisory Committee (SAC)
2009 – 2015	Member, Advisory Committee, BMC2 PCI Registry
2010 – 2015	Member, Advisory Committee, BMC2 PVI/ VIC Registry
2010 – 2015	Member, Investment Advisory Board, Venture Investors. Ann Arbor, MI
2014	<b>Co-Chair</b> , Washtenaw County American Heart Association Heart Ball Campaign
2015 – present	Member, Research Advisory Committee, Vascular Study Group of New England (VSGNE)

### **NATIONAL APPOINTMENTS**

1999 – present	Ad-hoc reviewer (American Heart Journal, American Journal of Cardiology, American Journal of Managed Care, Archives of Internal Medicine, Catheterization and Cardiovascular Intervention, Circulation,
----------------	---

Circulation - Cardiovascular Interventions, Cleveland Clinic Journal of Medicine, Coronary Artery Disease, Current Opinion in Medical Research, German Research Foundation Clinical Trials Programme Grants, International Journal of Cardiology, Journal of the American College of Cardiology, Journal of the American College of Cardiology – Cardiovascular Interventions, Journal of the American Heart Association, Journal of the American Medical Association, Lancet, Stroke, PIER Evidence Updates and the Evidence-Based Journals, Vascular Medicine)

- 1999 – 2000 Member, Clinical Events Committee, ASIS - 1107 trial
- 1999 – 2000 Member, Clinical Events Committee, GUSTO IV ACS trial
- 1999 – 2001 Member, Clinical Events Committee, TARGET trial
- 2000 – 2001 Member, Physician Advisory Board, *Weekly Briefings from the New England Journal of Medicine*
- 2002 Member, Clinical Events Committee, CardioGenesis PACIFIC/PEARL/PMR010 trials
- 2002 – 2003 Member, Clinical Events Committee, TriActiv trial
- 2003 – 2005 Physician Secretary, Myocardial Infarction Committee, American Board of Internal Medicine
- 2005 – 2012 Member, Steering Committee, NHLBI DYNAMIC Percutaneous Coronary Intervention Registry
- 2008 Abstract reviewer, 2009 American College of Cardiology Annual Scientific Session
- 2009 Abstract reviewer, Cardiovascular Research Technologies (CRT)
- 2009 Abstract reviewer, 2010 American College of Cardiology Annual Scientific Session
- 2009 – 2011 Member, Peripheral Arterial Disease Advisory Committee to the VA (PAC-VA)
- 2010 Abstract reviewer, 2011 American College of Cardiology Annual Scientific Session and Innovation in Intervention (i2) Summit
- 2011 Abstract reviewer, 2012 ACC-i2 with TCT
- 2011 – 2012 Member, Technical Expert Panel, Agency for Healthcare Research and Quality (AHRQ) Developing Evidence to Inform Decisions about

Effectiveness (DEcIDE) initiative on Real World Effectiveness of Carotid Artery Stenting in Medicare Patients

2012 – 2013	Member, Program Committee, Endovascular Intervention Working Group, TCT@ACC.13
2012 – 2014	<b>Chair</b> , Clinical Events Committee, ROADSTER plus trial
2012 – present	Member, Executive Committee, ENDOMAX trial
2013	Abstract reviewer, 2014 American College of Cardiology Annual Scientific Session
2014	Abstract reviewer, 2014 Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium
2014	Member, Scientific Committee, Transcatheter Cardiovascular Therapeutics 2014 Annual Scientific Symposium
2014	Abstract reviewer, 2015 American College of Cardiology Annual Scientific Session
2014	Abstract reviewer, 2015 Society for Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions
2014 – present	Member, Publications Committee, Patient-centered Outcomes Recovery from Treating peripheral Arterial disease: Investigating Trajectories (PORTRAIT)-Phase II study
2014 – present	Member, <b>Editorial Board</b> , <i>Vascular Medicine</i>
2014	<b>Guest Editor</b> , <i>Vascular Medicine</i>
2014 – present	Member, Scientific Advisory Board (non-paid), Silk Road Medical. Sunnyvale, CA
2015 – 2016	<b>Chair</b> , Clinical Events Committee. ROADSTER continued access registry
2015	Abstract reviewer, 2015 Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium
2015	Abstract reviewer, 2016 American College of Cardiology Annual Scientific Session
2015	Member, Scientific Committee, 2015 Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium



- 2015 – present Member, Research Advisory Committee. Society for Vascular Surgery Vascular Quality Initiative (SVS VQI).
- 2015 - present Member, MDEpiNet: Registry Assessment of Peripheral Interventional Devices (RAPID) Working Group
- 2016 Abstract reviewer, 2016 Society for Cardiovascular Angiography & Interventions Scientific Sessions
- 2016 Abstract reviewer, 2016 Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium
- 2016 Abstract reviewer, 2017 American College of Cardiology Annual Scientific Session
- 2017 Abstract reviewer, 2017 Society for Cardiovascular Angiography & Interventions Scientific Sessions
- 2017 Abstract reviewer, 2017 Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium
- 2017 Abstract reviewer, 2018 American College of Cardiology Annual Scientific Session
- 2017 - present Member, **Editorial Board**, *JACC: Cardiovascular Interventions*
- 2017 – present Member, **Editorial Board**, *Circulation*
- 2018 Abstract reviewer, 2018 Society for Cardiovascular Angiography & Interventions Scientific Sessions
- 2018 Abstract reviewer, 2018 Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium
- 2018 Abstract reviewer, 2019 American College of Cardiology Annual Scientific Session
- 2018 **Guest Editor**, *Vascular Medicine*
- 2019 Abstract reviewer, 2019 Society for Cardiovascular Angiography & Interventions Scientific Sessions
- 2019 – 2021 Member, **Editorial Board**, *Circulation Cardiovascular Interventions*
- 2019 – present Member, **Editorial Board**, *Cardiovascular Revascularization Medicine*

2019	Abstract reviewer, 2019 Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium
2019	<b>Guest Associate Editor</b> , <i>Circulation Cardiovascular Interventions</i>
2019-2020	<b>Editor</b> , <i>Interventional Cardiology Clinics</i> - Updates in Peripheral Vascular Intervention.
2019	Abstract reviewer, 2019 American College of Cardiology Annual Scientific Session
2019 – present	Member, US FDA Medical Device Epidemiology Network (MDEpiNet) Registry Assessment of Peripheral Interventional Devices (RAPID) Paclitaxel Portfolio (PTX-P) Working Group
2019 – present	<b>Vascular Medicine Section Editor</b> , <i>Journal of the American College of Cardiology</i>
2020 – 2023	Member, Scientific Oversight Committee, VQI DELTA NEST PTX analysis

#### MEMBERSHIP IN SOCIETIES

##### American College of Cardiology

1998 – 2005	Member
2005 – present	Fellow
2009 – 2014	Member, Peripheral Vascular Disease (PVD) Committee
2012 – 2014	<b>Chair</b> , American College of Cardiology Peripheral Vascular Disease Committee
2012 – 2017	PVD Council Liaison, Interventional Section Leadership Council
2012 – 2015	Member, Board of Governors ( <b>Governor</b> – State of Michigan)
2013 – 2014	Member, American College of Cardiology National Cardiovascular Disease Registry, CARE/ Peripheral Vascular Intervention Registry Transition Work Group
2014 – 2017	<b>Chair</b> , PVD Section Leadership Council & Member Section
2014 – 2017	Member, Steering Committee, National Cardiovascular Disease Registry PVI Registry

2014 – 2018	Member, Rating Panel, Peripheral Vascular Intervention Appropriate Use Criteria
2016 – 2019	Member, Annual Scientific Session Program Committee
2016 – 2018	Member, Test Materials Development Committee (TMDC) for the ACC in-training exam
2016 – 2018	Member, Writing Committee, Peripheral Artery Disease Measures Set Update
2016 – 2018	Member, Lower Extremity Peripheral Artery Disease Guideline Clinician Tool Work Group
2017 – 2020	Member, Interventional Section Leadership Council
2017 – 2018	<b>Past Chair</b> , PVD Section Leadership Council & Member Section
2019 – 2020	<b>Chair</b> , Interventional Section, Interventional Training Work Group
2019	Member, ACC.19 Live Cases Working Group

Michigan Chapter, American College of Cardiology

2005 – 2015	Member
2008 – 2011	Member, Interventional Cardiology Expert Standby Panel
2010 – 2015	Member, Chapter Council
2010 – 2015	Member, Annual Conference Planning Committee
2011	<b>Chair</b> , 23 <sup>rd</sup> Annual Chapter Conference. Traverse City, MI
2012	<b>Co-chair</b> , 24 <sup>th</sup> Annual Chapter Conference. Traverse City, MI
2013 – 2015	Member, Nominating Committee
2013- 2014	President Elect, Chapter Council
2014 – 2015	<b>President</b> , American College of Cardiology Foundation, Michigan Chapter

Rhode Island Chapter, American College of Cardiology

2015 – present	Member
2016 – present	Member, Executive Council

Society for Cardiovascular Angiography & Interventions

2003 – present	Member
2005 – present	Fellow
2010 – 2015	Member, Interventional Career Development Committee
2012 – 2019	Member, Peripheral Vascular Disease (PVD) Committee/Council
2012 – 2014	Member, Writing Committee, Expert Consensus Document on Iliac Intervention
2013 – 2014	<b>Co-chair</b> , Writing Committee, Society for Cardiovascular Angiography and Interventions Expert Consensus Document on Renal Sympathetic Denervation
2013 – 2015	<b>Chair</b> , Writing Committee, SCAI/SVM Clinical Competence Statement on Carotid Stenting: Training and Credentialing for Carotid Stenting – Multispecialty Consensus Recommendations
2013 – 2015	Member, Quality Improvement Committee
2013 – 2016	Member, Carotid Committee
2013 – 2015	Member, Planning Committee, Complex Peripheral Vascular Interventions (CPVI) 2015
2015 – 2016	Member, Writing Committee, SCAI Catheterization Laboratory Best Practices Expert Consensus Statement
2016 – 2019	Member, Education Committee
2017 – 2018	Peripheral Vascular <b>Track Director</b> , SCAI 2018 Annual Scientific Sessions
2017- 2020	Member, Board of Trustees
2018	Member, Publications Committee
2018	<b>Co-Chair</b> , SCAI Fall Fellows Course
2018 – present	<b>Chair</b> , Research Task Force
2018 – 2020	Member, Writing Committee, SCAI Consensus Guidelines for Device Selection in Aorto-Iliac Arterial Interventions
2019	Board of Trustee Liaison, PVD Council

2019 **Co-Chair**, SCAI Fall Fellows Course

2020 **Chair**, SCAI Fall Fellows Course

Society for Vascular Medicine

2005 – present Fellow

2007 – 2012 Member, Communications Committee

2012 – present **Trustee**

2014 – present Society for Vascular Medicine representative to the Society for Vascular Surgery Patient Safety Organization Governing Council (governing body over the Vascular Quality Initiative registry)

2015 – 2018 Member, Scientific Program Committee

2015 – 2019 **Secretary**

2015 – 2019 **Chair**, Membership Committee

2016 – 2017 **Co-director** 2017 SVM-SCAI Board Review Course

2019 – 2021 **President-Elect**

2019 – 2021 Member, Nominating Committee

American Heart Association

2006 – Member

2016 – 2018 Member, Writing Group, Health Literacy in Cardiovascular Disease--An Emerging Frontier in Primary and Secondary Prevention

2016 – 2018 Member, Lower Extremity Peripheral Artery Disease Guidelines Simulation Planning Committee; [learn.heart.org](http://learn.heart.org)

2017 – 2019 Member, Writing Group, Scientific Statement on Perfusion Assessment in Critical Limb Ischemia

2020 – 2021 **Vice-Chair**, 2021 Multispecialty Lower Extremity PAD Guidelines Writing Group

Michigan State Medical Society

2005 – 2015 Member

- 2007                    **Course Director**, “Peripheral Arterial Disease - Screening, Diagnosis and Management.” Michigan State Medical Society 142<sup>nd</sup> Annual Scientific Meeting. Troy, MI
- 2008                    **Course Director**, “Peripheral Arterial Disease, Screening, Diagnosis, and Management: A Case-Based Approach.” Michigan State Medical Society 143<sup>rd</sup> Annual Scientific Meeting. Troy, MI
- 2009 – 2011            Member, Annual Scientific Meeting Planning Committee
- 2009                    **Course Co-Director**, "Atherosclerotic cardiovascular disease: Diagnosis and management in multiple vascular beds." Michigan State Medical Society 144<sup>th</sup> Annual Scientific Meeting. Troy, MI
- 2010                    **Course Co-Director**, "A Multidisciplinary Approach to the Diagnosis and Treatment of Atherosclerotic Vascular Disease." Michigan State Medical Society 145<sup>th</sup> Annual Scientific Meeting. Troy, MI

Washtenaw County Medical Society

2006 – 2015            Member

PUBLICATIONS LIST

Original Publications in Peer-Reviewed Journals

1. Lockette W, McCurdy R, **Aronow H**, Butler B. Effect of 8-Bromo-Cyclic Guanosine Monophosphate on Intracellular pH and Calcium in Vascular Smooth Muscle. *Hypertension* 1989; 13:865-869.
2. **Aronow H**, Kim M, Rubenfire M: Silent Ischemic Cardiomyopathy and Left Coronary Ostial Stenosis Secondary to Radiation Therapy. *Clinical Cardiology* 1996; 19:260-2.
3. Hsi ED. Foreman KE. Duggan J. Alkan S. Kauffman CA. **Aronow HD**. Nickoloff BJ. Molecular and pathologic characterization of an AIDS-related body cavity-based lymphoma, including ultrastructural demonstration of human herpesvirus-8: a case report. *Am J Surg Pathol* 1998;22:493-9. Case report.
4. **Aronow HD**, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox R, Vahanian A, Armstrong P, Lauer MS. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes. *Lancet* 2001; 357: 1063-1068.
5. **Aronow HD**, Peyser PA, Eagle KA, Bates ER, Werns SW, Russman PL, Crum MA, Harris K, Moscucci M. Predictors of length of stay after coronary stenting. *Am Heart J* 2001; 142(5): 799-805.

6. Casserly IP, **Aronow HD**, Schoenhagen P, Tsutsui H, Popovich J, Goormastic M, Popma JJ, Nissen SE, Tuzcu EM. Relationship between residual atheroma burden and neointimal growth in patients undergoing stenting. *J Am Coll Cardiol* 2002;40:1573-8.
7. Novaro GM, **Aronow HD**, Militello MA, Garcia MJ, Mayer-Sabik E. Benzocaine-induced methemoglobinemia: Experience from a high-volume transesophageal echocardiography laboratory. *J Am Soc Echocardiogr* 2003;16:170-5.
8. Aronow SP, **Aronow HD**, Blanchard T, Czinn S, Chelimsky G. Hair relaxers: A benign caustic ingestion? *J Pediatr Gastroenterol Nutr* 2003;36:120-125.
9. L'Allier, PL, **Aronow HD**, Cura FA, Bhatt DL, Albirini A, Schneider JP, Topol EJ, Ellis SG. Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting. *Can J Cardiol* 2003;19:1041-6.
10. **Aronow HD**, Novaro GM, Lauer MS, Brennan DM, Lincoff AM, Topol EJ, Kereiakes, DJ, Nissen SE. In-hospital initiation of lipid-lowering therapy following **coronary** intervention is the strongest predictor of long-term utilization: A propensity analysis. *Arch Intern Med* 2003;163:2576-82.
11. Quinn MJ, **Aronow HD**, Califf RM, Bhatt DL, Sapp S, Kleiman NS, Harrington RA, Kong DF, Kandzari DE, Topol EJ. Aspirin dose and six-month outcome after an acute coronary syndrome. *J Am Coll Cardiol* 2004;43:972.
12. Novaro GM, **Aronow HD**, Mayer-Sabik E, Griffin BP. Plasma homocysteine and calcific aortic valve disease. *Heart* 2004;90:802-803.
13. Gurm HS, Lincoff AM, Kleiman NS, Kereiakes DJ, Tcheng JE, **Aronow HD**, Askari AT, Brennan DM, Topol EJ. Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. *Am J Cardiol* 2004;94:30-34.
14. **Aronow HD**, Shishehbor MH, Davis DA, Katzan IL, Bhatt DL, Bajzer CT, Abou-Chebl A, Krieger DW, Whitlow PL, Yadav JS. Leukocyte count predicts microembolic Doppler signals during carotid stenting: A link between inflammation and embolization. *Stroke* 2005;36:1910-1914.
15. **Aronow HD**, Lincoff AM, Quinn MJ, McRae AT, Gurm HS, Houghtaling PL, Granger CB, Harrington RA, Van de Werf F, Topol EJ, Lauer MS. Relation between prior lipid-lowering therapy and infarct size (creatinine kinase-MB level) among patients presenting with acute myocardial infarction. *Am J Cardiol* 2008;102:1119-24.
16. **Aronow HD**, Califf RM, Harrington RA, Vallee M, Graffagnino C, Shuaib A, Fitzgerald DJ, Easton JD, Van de Werf F, Diener HC, Ferguson JJ, Koudstaal PJ, Amarenco P, Theroux P, Davis S, Topol EJ. Relation between aspirin dose, all-cause mortality and bleeding in patients with recent cerebrovascular or coronary ischemic events from the BRAVO trial. *Am J Cardiol* 2008;102:1285-1290.

17. **Aronow HD**, Dutro MP, Kuznik A, Cwengros J. Cardiovascular comorbidities are prevalent and undertreated among statin users in both Medicare and commercial health plans. *Curr Res Med Opin* 2009;25:205-213.
18. **Aronow HD**, Steinhubl SR, Brennan DM, Berger PB, Topol EJ. Bleeding risk associated with one year of dual antiplatelet therapy following percutaneous coronary intervention: Insights from the CREDO trial. *Am Heart J* 2009;157:369-374.
19. **Aronow HD**, Hess G, Hill J, Kuznik A, Liu LZ. Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol. *Am J Ther* 2009;17:167-175.
20. Gualano SK, Gurm HS, Share D, Smith D, **Aronow HD**, LaLonde T, Bates ER, Changezi H, McNamara, Moscucci M. Temporal trends in the use of drug-eluting stents for approved and off-label indications: A longitudinal analysis of a large multi-center PCI registry. *Clin Cardiol* 2010;33:111-116.
21. Baldwin DE, Abbott JD, Trost JC, Vlachos HA, Selzer F, Glaser R, Wilensky RL, Slater JN, Doucet S, Naidu SS, **Aronow HD**, Williams DO. Comparison of Drug-Eluting and Bare Metal Stents for Saphenous Vein Graft Lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry). *Am J Cardiol* 2010;106:946-51.
22. **Aronow HD**, Strawderman, RL, Moscucci, M, Cowen ME. Duration of evidence-based medical therapy and the hazard for atherothrombotic events following percutaneous coronary intervention. *Int J Cardiol* 2010;153:262-6.
23. Kasapis C, Gurm HS, Chetcuti SJ, Munir K, Luciano A, Smith D, **Aronow HD**, Kassab EH, Knox MF, Moscucci M, Share D, Grossman PM. Defining the Optimal Degree of Heparin Anticoagulation for Peripheral Vascular Interventions: Insight from a Large Regional Multicenter Registry. *Circ Cardiovasc Interv* 2010;3:593-601.
24. **Aronow HD**, Gray WA, Ramee SR, Mishkel GJ, Schreiber TJ, Wang H. Predictors of Neurological Events Associated With Carotid Artery Stenting in High Surgical Risk Patients: Insights from the Cordis Carotid Stent Collaborative. *Circ Cardiovasc Interv* 2010;3:577-584.
25. Sharma A, Herrera B, **Aronow HD**. Simultaneous spontaneous coronary and vertebral artery dissections in a postpartum woman. Case Report. *J Invasive Cardiol* 2010;22:E229-232. Case report.
26. Sharma AM, Wilks J, **Aronow HD**. Recurrent coronary thrombus formation in setting of Diabetic Ketoacidosis. *J Invas Cardiol* 2011;23:E1-4. Case Report.
27. Thomas MP, Moscucci M, Smith DE, **Aronow H**, Share D, Kraft P, Gurm HS. Outcome of contemporary percutaneous coronary intervention in the elderly and the very elderly: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium *Clin Cardiol* 2011;34:549-554.



28. Cohen DJ, Stolker JM, Wang K, Magnuson EA, Clark WM, Demaerschalk BM, Sam AD, Elmore JR, Weaver FA, **Aronow HD**, Goldstein LB, Roubin GS, Howard G, Brott TG on behalf of the CREST Investigators. Health-Related Quality of Life after Carotid Stenting versus Carotid Endarterectomy: Results from the CREST Trial. *J Am Coll Cardiol* 2011;58:1557-1565.
29. Voeks, JH, Howard G, Roubin GS, Malas MB, Cohen DJ, Sternbergh WC, **Aronow HD**, Eskandari MK, Sheffet AJ, Lal BK, Meschia JF, Brott TG. Age and outcomes after carotid stenting and endarterectomy: The Carotid Revascularization Endarterectomy Versus Stenting Trial. *Stroke* 2011;42:3484-3490.
30. Slocum NK, Grossman PM, Moscucci M, Smith DE, **Aronow HD**, Dixon SR, Share D, Gurm HS. The changing definition of contrast-induced nephropathy and its clinical implications: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). *Am Heart J*. 2012;163(5):829-34.
31. Ardati AK, Kaufman SR, **Aronow HD**, Nypaver TJ, Bove PG, Gurm HS, Grossman PA. The Quality and Impact of Risk Factor Control in Patients with Stable Claudication Presenting for Peripheral Vascular Interventions. *Circ Cardiovasc Interv* 2012;5:850-855.
32. Wayangankar SA, Abu-Fadel MS, **Aronow HD**, Kennedy KF, Gupta R, Yeh RW, Gray WA, Rosenfield K, Hennebry TA. Hemorrhagic and ischemic outcomes following bivalirudin vs. unfractionated heparin during carotid artery stenting: A propensity analysis from the NCDR<sup>®</sup>. *Circ Cardiovasc Interv* 2013;6:131-138.
33. Ardati AK, Pitt B, Smith DE, **Aronow HD**, Share D, Moscucci M, Chetcuti S, Grossman PM, Gurm HS. Current medical management of stable coronary artery disease before and after elective percutaneous coronary intervention. *Am Heart J* 2013; 165:778-84.
34. Valle JA, Zhang M, Dixon S, **Aronow HD**, Share D, Naoum JB, Gurm HS. Impact of pre-procedural beta blockade on inpatient mortality in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction. *Am J Cardiol* 2013;111:1714-20.
35. Khambatta S, Seth M, Rosman HS, Share D, **Aronow HD**, Moscucci M, LaLonde T, Dixon SR, Gurm HS. The association between race, treatment and outcomes of patients undergoing contemporary percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) *Am Heart J* 2013;165:893-901.
36. Kanaan M, Seth M, **Aronow HD**, Wohns D, Dixon S, Share D, Gurm HS. The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin. *J Am Coll Cardiol* 2013;62:2083-2089.
37. Giri J, Kennedy KF, Weinberg I, Hawkins BM, Calfon M, Drachman D, McCormick DJ, **Aronow HD**, White CJ, Rosenfield K, Yeh RW. Comparative Effectiveness of Commonly Used Devices for Carotid Artery Stenting: An NCDR Analysis. *JACC Interv* 2014;7:171-177.

38. Kanaan M, Seth M, **Aronow HD**, Naous J, Wunderly D, Mitchiner J, Moccucci M, Gurm HS. Pre-procedural statin use in patients undergoing percutaneous coronary intervention. *Am Heart J* 2014;168:110-6.
39. Muthappan P, Smith D, **Aronow HD**, Eagle K, Wohns D, Fox J, Share D, Moscucci M, Gurm HS. The epidemiology and outcomes of percutaneous coronary intervention before high risk non-cardiac surgery in contemporary practice: Insights from the BMC2 registry. *J Am Heart Assoc* 2014;3:e000388.
40. **Aronow HD**, Gurm HS, Blankenship JC, Czeisler CA, Wang TY, McCoy LA, Neely ML, Spertus JA. Middle-of-the-night PCI and its association with PCI outcomes performed the following day: An analysis from the NCDR. *JACC Cardiovasc Interv* 2015;8:49-56.
41. Jalbert JJ, Nguyen LL, Gerhard-Herman MD, Jaff MR, White CJ, Rothman AT, Seeger JD, Kumamaru H, Williams LA, Chen C-Y, Liu J, Tsai TT, **Aronow HD**, Johnston JA, Brott TG, Setoguchi S. Outcomes After Carotid Artery Stenting in Medicare Beneficiaries 2005-2009. *JAMA Neurology* 2015;72:276-86.
42. Wayangankar SA, Kennedy KF, **Aronow HD**, Rundback J, Tafur A, Drachman D, Patel B, Sivaram CA, Latif F. Racial/Ethnic Variation in Carotid Artery Revascularization Utilization and Outcomes: Analysis From the National Cardiovascular Data Registry. *Stroke* 2015;46:1525-1532.
43. Hawkins BM, Kennedy KF, **Aronow HD**, Nguyen LL, White CJ, Rosenfield K, Normand SLT, Spertus JA, Yeh RW. Hospital Variation in Carotid Stenting Outcomes. *J Am Coll Cardiol Intv* 2015;8:858-63.
44. Parsh J, Seth M, **Aronow HD**, Dixon S, Heung M, Mehran R, Gurm HS. Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug Dosing Recommendations and Risk Stratification in Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions. *J Am Coll Cardiol* 2015;65:2714-23.
45. Renard BM, Seth M, Share D, **Aronow HD**, Laveroni EW, De Gregorio M, Hans SS, Henke PK, Gurm HS, Grossman PM. If Not Now, When? Prescription of Evidence-Based Medical Therapy Prior to Hospital Discharge Increases Utilization at Six Months in Patients with Symptomatic Peripheral Artery Disease. *Vasc Med* 2015;20:544-50.
46. Jalbert JJ, Gerhard-Herman MD, Nguyen LL, Jaff MR, Kumamaru H, Williams LA, Chen CY, Liu J, Seeger JD, Rothman AT, Schneider P, Brott TG, Tsai TT, **Aronow HD**, Johnston JA, Setoguchi S. Relationship Between Physician and Hospital Volume and Mortality After Carotid Artery Stenting Among Medicare Beneficiaries. *Circ Cardiovasc Qual Outcomes* 2015;8:S81-9.
47. Kimmelstiel C, Pinto D, MD, **Aronow HD**, Weintraub AR, Dangas G, FanW , Prats J, Deliargyris EN, Katzen BT. Bivalirudin Is Associated With Improved In-Hospital Outcomes Compared With Heparin in Percutaneous Vascular Interventions: Observational, Propensity-Matched Analysis From the Premier Hospital Database. *Circ Cardiovasc Interv* 2016;9:e002823. DOI: 10.1161/CIRCINTERVENTIONS.115.002823.

48. Jalbert JJ, Nguyen LL, Gerhard-Herman MD, Kumamaru H, Chen CY, Williams LA, Liu J, Rothman AT, Jaff MR, Seeger JD, Benenati JF, Schneider PA, **Aronow HD**, Johnston JA, Brott TG, Tsai TT, White CJ, Setoguchi S. Comparative Effectiveness of Carotid Artery Stenting Versus Carotid Endarterectomy Among Medicare Beneficiaries. *Circ Cardiovasc Qual Outcomes* 2016;9:275-285.
49. **Aronow HD**, Kennedy KF, Wayangankar SA, Katzen BT, Schneider PA, Abou-Chebl A, Rosenfield, KA. Prescription of guideline-based medical therapies at discharge following carotid artery revascularization: An NCDR® analysis. *Stroke* 2016;47:2339-46.
50. Omran J, Abdullah O, Abu-Fadel, M Gray WA, Firwana B, Drachman DE, Mahmud E, **Aronow HD**, White CJ, Al-Dadah AS. Hemorrhagic and ischemic outcomes of Heparin vs. Bivalirudin in carotid artery stenting: A meta-analysis of studies. *Catheter Cardiovasc Interv* 2016;89:746-753.
51. Omran J, Mahmud E, White CJ, **Aronow HD**, Drachman DE, Gray W, Abdullah O, Abu-Fadel M, Firwana B, Mishkel G, Ad-Dadah AS. Proximal balloon occlusion versus distal filter protection in carotid artery stenting: A meta-analysis and review of the literature. *Catheter Cardiovasc Interv* 2016;89:923-931.
52. Sardar P, Chatterjee S, **Aronow HD**, Kundu A, Ramchand P, Mukherjee D, Nairooz R, Gray WA, White CJ, Jaff MR, Rosenfield K, Giri J. Carotid Artery Stenting vs. Endarterectomy for Stroke Prevention: An Updated Meta-Analysis. *J Am Coll Cardiol* 2017;69:2266-2275.
53. Roumia M, **Aronow HD**, Soukas P, Gosch K, Smolderen KG, Spertus JS, Abbott JD. Sex differences in disease-specific health status measures in patients with symptomatic peripheral arterial disease: Data from the PORTRAIT study. *Vasc Med* 2017;22:103-109.
54. Grossman P, Ali S, **Aronow HD**, Boros M, Nypaver T, Schreiber TL, Park Y, Henke P, Gurm H. Contrast-Induced Nephropathy in Patients Undergoing Endovascular Peripheral Vascular Intervention: Incidence, Risk Factors, and Outcomes As Observed in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. *J Interv Cardiol* 2017;30:274-280.
55. Sardar MR, Khan ZA, Abraham A, Saeed W, Farhan M, Kolte D, Sharaf B, Gordon P, Sellke F, Sodha NR, **Aronow HD**, Ehsan A. Management strategies and possible risk factors for ventricular septal defects after transcatheter aortic valve replacement: Case series from a single center and review of literature. *Cardiovasc Revasc Med* 2017;18:462-470.
56. Kolte D, Kennedy KF, Shishehbor MH, Abbott JD, Khera S, Soukas P, Mamdani ST, Hyder ON, Drachman DE, **Aronow HD**. Thirty-Day Readmissions After Endovascular or Surgical Therapy for Critical Limb Ischemia: Analysis of the 2013-2014 Nationwide Readmissions Databases. *Circulation* 2017;136:167-176.
57. Khera S, Kolte D, Gupta T, Goldsweig A, Velagapudi P, Kalra A, Tang GHL, Aronow WS, Fonarow GC, Bhatt DL, **Aronow HD**, Kleiman NS, Reardon M, Gordon PC, Sharaf B,

- Abbott JD. Association Between Hospital Volume and 30-Day Readmissions Following Transcatheter Aortic Valve Replacement. *JAMA Cardiol* 2017;2:1732-1741.
58. Enezate T, Omran J, Al-Dadah A, Mahmud E, Patel M, **Aronow HD**, Bhatt DL. Comparison of Outcomes of ST-Elevation Myocardial Infarction Treated by Percutaneous Coronary Intervention During Off-Hours Versus On-Hours. *Am J Cardiol* 2017;120:1742-1754.
  59. Enezate T, Omran J, Al-Dadah AS, Alpert M, White CJ, Abu-Fadel M, Aronow HD, Cohen M, Aguirre F, Patel M, Mahmud E. Fractional flow reserve versus angiography guided percutaneous coronary intervention: An updated systematic review. *Catheter Cardiovasc Interv* 2017 [published online before print] DOI 10.1002/ccd.27302
  60. Kolte D, Sardar P, Khera S, Zeymer U, Thiele H, Hochadel M, Radovanovic D, Erne P, Hambraeus K, James S, Claessen BE, Henriques JPS, Mylotte D, Garot P, Aronow WS, Owan T, Jain D, Panza JA, Frishman WH, Fonarow GC, Bhatt DL, **Aronow HD**, Abbott JD. Culprit Vessel Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Elevation Myocardial Infarction: A Collaborative Meta-Analysis. *Circ Cardiovasc Interv* 2017 [published online before print] DOI 10.1161/CIRCINTERVENTIONS.117.005582
  61. Velagapudi P, Turagam M, Kholte D, Khera S, Parikh P, Hyder, O, **Aronow H**, Abbott, D. Less than two versus greater than two hour invasive strategy in non-ST elevation myocardial infarction: a meta-analysis of randomized controlled trials. *Expert Rev Cardiovasc Ther* 2017;16:67-72.
  62. Lima F, Kolte D, Kennedy K, Yen TY, Abbott JD, Soukas P, Hyder O, Mamdani ST, **Aronow HD**. Endovascular versus Surgical Revascularization for Chronic Mesenteric Ischemia: Insights from the National Inpatient Sample Database. *JACC Cardiovasc Interv* 2017;10:2440-2447.
  63. Goldsweig AM, Kennedy K, Kolte D, Abbott JD, Gordon PC, Sharaf BL, Sellke FW, Ehsan A, Sodha NR, **Aronow HD**. Predictors of Radiation Dosage in Transcatheter Aortic Valve Replacement. *Catheter Cardiovasc Interv* 2017;92:768-774.
  64. Omran J, Enezate T, Abdullah O, Al-Dadah AS, **Aronow HD**, Mustapha J, Saab F, S. Brilakis E, Reeves R, Bhatt DL, Mahmud E. Bivalirudin versus unfractionated heparin in peripheral vascular interventions. *Cardiovasc Revasc Med* 2018. <https://doi.org/10.1016/j.carrev.2018.01.010>
  65. Jones WS, Krucoff M, Morales J, Wilgus R, Heath A, Williams M, Tchong J, Malone M, Reed T, Marinac-Dabic D, Fukaya R, Lookstein R, Handa N, **Aronow HD**, Bertges D, Jaff M, Tsai T, Smale J, Zaugg M, Thatcher R, Cronenwett J. Registry Assessment of Peripheral Interventional Devices (RAPID): Registry Assessment of Peripheral Interventional Devices Core Data Elements. Co-publication in *J Vasc Surg* 2018;67:637-44, *Circ J* 2018;82:316-22.

66. Noyes AM, Abbott JD, Gosch K, Smolderen K, Spertus JA, Hyder O, Soukas PA, Shishehbor MH, **Aronow HD**. Association Between Patient Characteristics and Baseline Health Status Among an International Cohort of Claudicants: An Analysis From the Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT) Registry. *Vascular Medicine* 2018;23:32-38.
67. Gupta T, Kolte D, Khera S, Agarwal N, Villablanca PA, Goel K, Patel K, Aronow WS, Wiley J, Bortnick AE, **Aronow HD**, Abbott JD, Pyo RT, Panza JA, Menegus MA, Rihal CS, Fonarow GC, Garcia MJ, Bhatt DL. Sex Differences in Management and Outcomes of Non-ST-elevation Myocardial Infarction in the United States. *Circ Cardiovasc Interv* 2018;11: e005735.
68. Smolderen KG, Gosch K, Patel M, Jones WS, Hirsch AT, Beltrame J, Fitridge R, Shishehbor RH, Denollet J, Vriens, Jan Heyligers P, Stone N, **Aronow H**, Abbott JD, Labrosciano C, Tutein-Nolthenius R, Spertus, JA. PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories): Overview of Design and Rationale of an International Prospective Peripheral Arterial Disease Study. *Circ Cardiovasc Qual Outcomes*. 2018;11:e003860. doi: 10.1161/CIRCOUTCOMES.117.003860
69. Goldsweig AM, Wang Y, Forrest JK, Cleman MW, Minges KE, Mangi AA, **Aronow HD**, Krumholz HM, Curtis JP. Ventricular Septal Rupture Complicating Acute Myocardial Infarction: Incidence, Treatment, and Outcomes Among Medicare Beneficiaries 1999-2014. *Catheter Cardiovasc Interv* 2018
70. Kolte D, Khera S, Vemulapalli S, Dai D, Heo S, Goldsweig A, **Aronow HD**, Elmariah S, Inglessis I, Palacios IF, Sharaf BL, Gordon, PC, Abbott JD. Outcomes Following Urgent/Emergent Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry. *JACC Cardiovasc Interv* 2018;11:1175-1185.
71. Gupta T, Khera S, Kolte D, Goel K, Kalra A, Villablanca PA, **Aronow HD**, Abbott JD, Fonarow GC, Taub CC, Kleiman NS, Weisz G, Inglessis I, Elmariah S, Rihal CS, Garcia M, Bhatt DL. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Coronary Artery Bypass Grafting: Trends in Utilization and Propensity-Score Matched Analysis of In-hospital Outcomes. *Circ Cardiovasc Interv* 2018;11:e006179. DOI: 10.1161/CIRCINTERVENTIONS.117.006179
72. Echouffo-Tcheugui JB, Kolte D, Khera S, **Aronow HD**, Abbott JD, Bhatt DL and Fonarow GC. Diabetes Mellitus and Cardiogenic Shock Complicating Acute Myocardial Infarction. *Am J Med*. 2018;131:778-786 e1
73. Louis DW, Kennedy K, Lima FV, Pancholy S, Abbott JD, Gordon P, **Aronow HD**. Association Between Maximal Activated Clotting Time and Major Bleeding Complications During Transradial and Transfemoral Percutaneous Coronary Intervention. *JACC Cardiovasc Interv* 2018;11:1036-1045.
74. Bavishi C, Lemor A, Trivedi V, Chatterjee S, Moreno P, Lasala J, **Aronow HD**, Abbott JD. Etiologies and predictors of 30-day readmissions in patients undergoing percutaneous

mechanical circulatory support-assisted percutaneous coronary intervention in the United States: Insights from the Nationwide Readmissions Database. *Clin Cardiol*. 2018;41:450-457.

75. Velagapudi P, Turagam M, Kolte D, Khera S, Hyder O, Gordon P, **Aronow HD**, Leopold J, Abbott JD. Intramyocardial autologous CD34+ cell therapy for refractory angina: A meta-analysis of randomized controlled trials. *Cardiovasc Revasc Med*. 2018.
76. Velagapudi P, Kolte D, Ather K, Khera S, Gupta T, Gordon PC, **Aronow HD**, Kirtane AJ and Abbott JD. Temporal Trends and Factors Associated With Prolonged Length of Stay in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Am J Cardiol*. 2018;122:185-191.
77. Khera S, Villablanca PA, Kolte D, Gupta T, Hasan Khan M, Velagapudi P, Kalra A, Kleiman N, **Aronow HD**, Abbott JD, Rosenfield K, Drachman DE, Bangalore S, Bhatt DL and Naidu SS. Long-Term Outcomes of Drug-Eluting Stents Versus Bare-Metal Stents in End-Stage Renal Disease Patients on Dialysis: A Systematic Review and Meta-Analysis. *Cardiol Rev*. 2018;26:277-286.
78. Shammass NW, Pucillo A, Jenkins JS, Garcia LA, Davis T, **Aronow HD**, Armstrong EJ, Zeller T, Scheinert D, Rosenschein U and Gray W. WIRION Embolic Protection System in Lower Extremity Arterial Interventions: Results of the Pivotal WISE LE Trial. *JACC Cardiovasc Interv*. 2018;11:1995-2003.
79. Kolte D, Goldsweig A, Abbott JD, Gordon P, Sellke FW, Ehsan A, Sodha N, Sharaf B, **Aronow HD**. Comparison of incidence, predictors and outcomes of early infective endocarditis after transcatheter aortic valve implantation versus surgical aortic valve replacement in the United States. *Am J Cardiol* 2018;122:2112-2119.
80. Apostolidou E, Ehsan A, Beale CE, Kolte D, Kennedy KF, Sellke FW, Gordon PC, Sharaf B, **Aronow HD**. Association between red blood cell transfusion and 30-day readmission following transcatheter aortic valve replacement. *Structural Heart* 2018. DOI: 10.1080/24748706.2018.1529448.
81. Johnston AL, Vemulapalli S, Gosch KL, **Aronow HD**, Abbott JD, Patel MR, Smolderen KG, Shishebor M, Spertus J, Jones WS. Ankle-brachial index in patients with intermittent claudication is a poor indicator of patient-centered and clinician-based evaluations of functional status. *J Vasc Surg* 2019;69:906-12.
82. Goldsweig AM, Kennedy KF, Abbott JD, Schuyler Jones W, Velagapudi P, Rutar FJ, Curtis JC, Tsai TT, **Aronow HD**. Patient Radiation Dosage During Lower Extremity Endovascular Intervention. *JACC Cardiovasc Interv* 2019;12:473-80.
83. Sardar P, Bhatt DL, Kirtane AJ, Kennedy KF, Chatterjee S, Giri J, Soukas PA, White WB, Parikh SA, **Aronow HD**. Catheter-Based Renal Denervation in Patients with Hypertension: A Meta-Analysis of Sham-Controlled Randomized Trials. *J Am Coll Cardiol* 2019;73:1633-42.

84. Sardar P, Giri J, Jaff MR, Parikh SA, Kundu A, White CJ, Chatterjee S, Kennedy KF, Desai NR, Hyder ON, Mukherjee D, Shishehbor MH, Abbott JD, **Aronow, HD**. Strength of Evidence Underlying the American Heart Association/ American College of Cardiology Guidelines on Endovascular and Surgical Treatment of Peripheral Vascular Disease. *Circ Cardiovasc Interv*. 2019;12:e007244
85. Apostolidou E, **Aronow HD**, Beale CE, Kolte D, Kennedy KF, Sellke FW, Gordon PC, Sharaf B, Ehsan A. Association Between Red Blood Cell Transfusion and Clinical Outcomes Among Patients Undergoing Transcatheter Aortic Valve Replacement. *Ann Thorac Surg*. 2019;107:1791-1798
86. Lima FV, Kolte D, Louis DW, Kennedy KF, Abbott JD, Soukas PA, Hyder ON, Mamdani ST and **Aronow HD**. Thirty-day readmission after endovascular or surgical revascularization for chronic mesenteric ischemia: Insights from the Nationwide Readmissions Database. *Vasc Med*. 2019;24:216-223.
87. Kolte D, Beale C, **Aronow HD**, Kennedy KF, Apostolidou E, Sellke FW, Sharaf BL, Gordon PC, Abbott JA, Ehsan A. Trends and Outcomes of Red Blood Cell Transfusion in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States. *J Thorac Cardiovasc Surg* 2019 [*in press*]
88. Abdelaziz HK, Saad M, Pothineni NVK, Megaly M, Potluri R, Saleh M, Lai Chin Kon D, Roberts DH, Bhatt DL, **Aronow HD**, Abbott JD, Mehta JL. Aspirin for Primary Prevention of Cardiovascular Events. *J Am Coll Cardiol* 2019;73:2915-2929.
89. Bhardwaj B, Spertus J, Kennedy K, Jones S, Safley D, Tsai T, **Aronow HD**, Vora A, Pokharel Y, Attaran RR, Feldman D, Salisbury A. Bleeding complications in peripheral vascular interventions: Insights from the NCDR PVI registry. *JACC Cardiovasc Interv* 2019;12:1140-1149.
90. Bavishi C, Chugh Y, Kimura T, Natsuaki M, Kaiser C, Gordon P, **Aronow HD**, Abbott JD. Biodegradable Polymer Drug-Eluting Stent versus Contemporary Durable Polymer Drug-Eluting Stents in Patients with Diabetes: A Meta-analysis of Randomized Controlled Trials. *Eur Heart J Qual Care Clin Outcomes*. 2019 (DOI 10.1093/ehjqcco/qcz031).
91. Goldsweig AM, Tak HJ, Chen LW, **Aronow HD**, Shah B, Kolte DS, Velagapudi P, Desai N, Szerlip M and Abbott JD. The Evolving Management of Aortic Valve Disease: 5-Year Trends in SAVR, TAVR, and Medical Therapy. *Am J Cardiol*. 2019 (DOI 10.1016/j.amjcard.2019.05.044).
92. Jones WS, Kennedy KF, Hawkins BM, Attaran RR, Secemsky EA, Latif F, Shammam NW, Feldman DN, **Aronow HD**, Gray B, Armstrong EJ, Grossman PM, Ho KKL, Prasad A, Jaff MR, Rosenfield K and Tsai TT. Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry. *Am Heart J*. 2019;216:74-81.

93. Elbadawi A, Saad M, Elgendy IY, Barssoum K, Omer MA, Soliman A, Almahmoud MF, Ogunbayo GO, Mentias A, Gilani S, Jneid H, **Aronow HD**, Kleiman N, Abbott JD. Temporal trends and outcomes of transcatheter versus surgical aortic valve replacement for bicuspid aortic valve stenosis. *J Am Coll Cardiol Intv* 2019;12:1811–22.
94. Kopin D, Seth M, Sukul D, Dixon S, **Aronow HD**, Lee D, Tucciarone M, Pielsticker E, Gurm HS. Primary and secondary vascular access site complications associated with percutaneous coronary intervention: Insights from the BMC2 Registry. *J Am Coll Cardiol Intv* 2019 [*in press*]
95. Beyer S, Shanafelt C, Pinto, D, Weinstein Z, **Aronow HD**, Weinberg I, Yeh R, Secemsky E, Carroll B. Utilization and outcomes of thrombolytic therapy for acute pulmonary embolism: A nationwide cohort study. *Chest* 2019 [*in press*] DOI: 10.1016/j.chest.2019.10.049.
96. Baig M, Imran HM, **Aronow HD**, Hyder ON. Endovascular revascularization of superficial femoral artery stent occlusion by combined retrograde access with catheter-directed thrombolysis and pharmaco-mechanical thrombectomy. *Cardiovasc Revasc Med* 2019 [*in press*]. Case Report. DOI: 10.1016/j.carrev.2019.10.027
97. Elbadawi A, Elgendy IY, Elzeneini M, Mentias A, Elsherbeny AM, Abbott JD, **Aronow H**, Sorajja P, Jneid H, Bhatt DL. Temporal trends and outcomes of transcatheter mitral valve repair and surgical mitral valve intervention in patients with prior CABG. *J Am Coll Cardiol Intv* 2019;23:2445-2447.
98. Lima FV, Kolte D, Rofeberg V, Molino J, Zhang Z, Elmariah S, **Aronow HD**, Abbott JD, Ben Assa E, Khera S, Gordon PC, Inglessis I and Palacios IF. Thirty-day readmissions after transcatheter versus surgical mitral valve repair in high-risk patients with mitral regurgitation: Analysis of the 2014–2015 Nationwide readmissions databases. *Catheter Cardiovasc Interv* 2020 [*in press*].
99. Gupta R, Ammari Z, Dasa O, Ruzieh M, Burlen JJ, Shunnar KM, Nguyen HT, Xie Y, Brewster P, Chen T, **Aronow HD**, Cooper CJ. 2019. Long-term mortality after massive, submassive, and low-risk pulmonary embolism. *Vasc Med* 2019 DOI: 10.1177/1358863X19886374 [*online before print*].
100. Lima FV, Kennedy KF, Kolte D, Wang L, Abbott JA, Soukas P, **Aronow, HD**. Thirty-Day Readmissions After Carotid Artery Stenting and Endarterectomy: Insights from the Nationwide Readmissions Database. *Circ Cardiovasc Interv* 2020;13: e008508. DOI 10.1161/CIRCINTERVENTIONS.119.008508.
101. Kolte D, Kennedy KF, Shishehbor MH, Soukas P, Hyder ON, Mandani ST, **Aronow HD**. Endovascular Versus Surgical Revascularization for Acute Limb Ischemia: A Propensity-Matched Analysis of the National Inpatient Sample. *Circ Cardiovasc Interv.* 2020;13:e008150. DOI 10.1161/CIRCINTERVENTIONS.119.008150.
102. Louis DW, Lima FV, Kolte D, Kennedy KF, Abbott D, **Aronow HD**. Thirty-Day Readmissions After Medical vs. Endovascular Therapy for Atherosclerotic Renal Artery



Stenosis: Insights from the Nationwide Readmissions Database. *Am J Cardiol* 2020;125:1115-1122.

103. Giannopoulos S, Trinidad E, **Aronow H**, Soukas P and Armstrong EJ. Endovascular Repair of Extracranial Carotid Artery Aneurysms: A Systematic Review. *Vasc Endovascular Surg*. 2020;54:254-263. DOI 10.1177/1538574419895383.
104. Elbadawi A, Elgendy IY, Megaly M, Saad M, Garcia S, Abbott JD, **Aronow H**, Gafoor S, Jneid H and Sorajja P. Temporal Trends and Outcomes of Transcatheter Mitral Valve Repair Among Nonagenarians. *JACC Cardiovasc Interv*. 2020. DOI 10.1016/j.jcin.2019.11.026.
105. Rymer JA, Kennedy KF, Lowenstern AM, Secemsky EA, Tsai TT, **Aronow HD**, Prasad A, Gray B, Armstrong EJ, Rosenfield K, Shishehbor MH and Jones WS. In-Hospital Outcomes and Discharge Medication Use Among Patients With Critical Limb Ischemia Versus Claudication. *J Am Coll Cardiol*. 2020;75:704-706. DOI 10.1016/j.jacc.2019.11.053.
106. Kokkinidis DG, Chaitidis N, Giannopoulos S, Texakalidis P, Haider MN, **Aronow HD**, Giri JS and Armstrong EJ. Presence of Contralateral Carotid Occlusion Is Associated With Increased Periprocedural Stroke Risk Following CEA but Not CAS: A Meta-analysis and Meta-regression Analysis of 43 Studies and 96,658 Patients. *J Endovasc Ther*. 2020;27:334-344. DOI 10.1177/1526602820904163.
107. Garg R, Fu D, McRee C, Anderson K, Kennedy K, **Aronow HD**, Tuohy C and Abbott JD. Outcomes of transradial approach to percutaneous coronary intervention in end-stage renal disease patients on dialysis. *Cardiovasc Revasc Med*. 2020. DOI 10.1016/j.carrev.2020.01.017.
108. Lemor A, Basir MB, Patel K, Kolski B, Kaki A, Kapur N, Riley R, Finley J, Goldsweig A, **Aronow HD**, Belford PM, Tehrani B, Truesdell AG, Lasorda D, Bharadwaj A, Hanson I, LaLonde T, Gorgis S, O'Neill W and National Cardiogenic Shock Initiative I. Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Cardiogenic Shock. *JACC Cardiovasc Interv*. 2020;13:1171-1178.
109. Goldsweig AM, Tak HJ, Chen LW, **Aronow HD**, Shah B, Kolte D, Desai NR, Szerlip M, Velagapudi P and Abbott JD. Relative Costs of Surgical and Transcatheter Aortic Valve Replacement and Medical Therapy. *Circ Cardiovasc Interv*. 2020;13:e008681.
110. Mohammed M, Gosch K, Safley D, Jelani QU, **Aronow HD**, Mena C, Shishehbor MH, Spertus JA, Abbott JD and Smolderen KG. Cilostazol and peripheral artery disease-specific health status in ambulatory patients with symptomatic PAD. *Int J Cardiol*. 2020.

#### Other Peer-Reviewed Publications

1. **Aronow HD**. Cholesterol-lowering therapy: Too often, too little, or too late? *Resident Research & Review* 2001;1:17-22. Review.
2. **Aronow HD**, Lauer MS. Lipid-lowering therapy is associated with an early mortality reduction after acute coronary syndromes. *Card Rev* 2002;19:11-16. Review.

3. **Aronow HD.** Lipid-lowering therapy is associated with reduced early mortality after acute coronary syndromes. *Acute Coronary Syndromes* 2002;5:10-16. Review.
4. **Aronow HD.** The Myocardial Ischemia Reduction with Acute Cholesterol Lowering trial: MIRACuLous or not, it's time to change current practice. *Curr Cont Trials Cardiovasc Med* 2002;3:3. Editorial.
5. Messerli A, **Aronow H**, Sprecher D. The Lescol Intervention Prevention Study (LIPS): Starting a statin immediately after PCI. *Cleve Clin J Med* 2003; 70:561-66. Review.
6. **Aronow HD**, Yadav JS. Embolic Protection for Carotid Artery Stenting – A ‘No Brainer.’ *Acta Chirurgica Belgica* 2004;104:65-70. Review.
7. **Aronow HD**, Sachar R, Tuzcu EM. Primary and secondary prevention of cardiovascular disease. In: Roffi M, Meier B, Topol EJ, eds: *CVMstat. A Handheld Computer-Based Approach to CardioVascular Medicine*. 1<sup>st</sup> Edition. Little Rock, AS. Handheldmed Inc, 2004. Review.
8. Roghatgi, S, **Aronow HD**. “Detection and Management of Aspirin Resistance.” *Crit Pathways in Cardiol* 2004;3:177-183. Review.
9. Stone GW, **Aronow HD**. “Long-term care after percutaneous coronary intervention: Focus on the role of antiplatelet therapy.” *Mayo Clin Proc.* 2006;81:641-652. Review.
10. **Aronow HD.** Identification and Management of Peripheral Arterial Disease in the Elderly. *Am J Cardiovasc Drugs* 2008;8(6):353-364. Review.
11. **Aronow HD**, Hiatt WR. The burden of peripheral artery disease and the role of antiplatelet therapy. *Postgraduate Medicine* 2009; 121:123-135. Review.
12. **Aronow HD.** Adding clopidogrel to proton-pump inhibitors was not associated with increased cardiovascular risk in myocardial infarction. *ACP Journal Club* 2010;153:JC6-13. Commentary.
13. **Aronow HD.** Heparin dose and harm: Absence of evidence or evidence of absence? *J Invasive Cardiol* 2012;24:157-158. Editorial.
14. Wayangankar S, **Aronow HD.** Nonemergency PCI without onsite cardiac surgery was noninferior to PCI with onsite services for MACE. *ACP Journal Club* 2013;159:JC6. Commentary.
15. Klein AJ, Feldman DN, **Aronow HD**, Gray BH, Gupta K, Gigliotti OS, Jaff MR, Bersin RM, White CJ. Appropriate use criteria: A society for cardiovascular angiography and intervention (SCAI) consensus statement for aorto-iliac arterial intervention. *Catheter Cardiovasc Interv* 2014;84:520-8. Guideline.
16. **Aronow HD**, Li J, Parikh SA. Where and when Device Therapy May Be Useful in the Management of Drug-Resistant Hypertension. *Curr Cardiol Rep* 2014;16:546. Review.

17. White WB, Turner JR, Sica D, Bisognano JD, Calhoun DA, Townsend RR, **Aronow HD**, Bhatt DL, Bakris GL. Detection, Evaluation, and Treatment of Severe and Resistant Hypertension: Proceedings from an American Society of Hypertension Interactive Forum held in Bethesda, Maryland, USA, October 10<sup>th</sup>, 2013, J Am Soc Hypertens 2014;8:743-57. Guideline.
18. **Aronow HD**, Collins TJ, Gray WA, Jaff MR, Kluck BW, Patel RA, Rosenfield KA, Safian RD, Sobieszczyk PS, Wayangankar SA, White CJ. SCAI/SVM Expert Consensus Statement on Carotid Stenting: Training and Credentialing for Carotid Stenting. Catheter Cardiovasc Interv 2015 (*Online before print*). Guideline.
19. Naidu SS, **Aronow HD**, Box LC, Duffy PL, Kolansky, DM, Kupfer, JM, Latif F, Mulukutla, SR, Rao SV, Swaminathan RV, Blankenship JC. SCAI expert consensus statement: 2016 Best Practices in the Cardiac Catheterization Laboratory. Catheter Cardiovasc Interv 2016;88:407-23. Guideline.
20. Shishehbor MH, **Aronow HD**, Bartholomew JR, Beckman JA, Froehlich JB, Lookstein R, Misra S, Roberts AC, Rosenfield K, Jaff MR. Vascular Specialist Response to Medicare Evidence Development Coverage Advisory Committee (MEDCAC) Panel on Peripheral Artery Disease of the Lower Extremities. Simultaneously published in: Catheter Cardiovasc Interv 2016;87:1181-6, Vasc Med 2016;21:281-6, J Am Coll Radiol 2016 (*online before print*). Editorial.
21. **Aronow HD**, Beckman JA. Parsing Atherosclerosis: The Unnatural History of PAD. Circulation 2016;134:438-40. Editorial.
22. **Aronow HD**, Hyder O. The Future of Endovascular Therapy: A View From The Cockpit. Editorial. J Am Coll Cardiol Intv 2016;9:2065-2066. Editorial.
23. Feldman DN, **Aronow HD**, Swaminathan RV, Abbott DJ, Tremme JA, Kapur NK, Breinholt JP, Asgar AW, Pinto DS, Tu TM, Rosenfield KM, Naidu SS. Investing in our future: Update on the SCAI Emerging Leader Mentorship (ELM) Program. Catheter Cardiovasc Interv 2016;88:674-677. Editorial.
24. Heo S, **Aronow HD**. Is common femoral artery stenosis still a surgical disease? In Armstrong E. Interv Cardiol Clin 2017;6:181-187. Review.
25. Goldsweig AM, Abbott JD, **Aronow HD**. Physician and Patient Radiation Exposure During Endovascular Procedures. Curr Treat Options Cardiovascular Med 2017;19(2)10. Review.
26. Shishehbor MH, **Aronow HD**. Readmissions for Critical Limb Ischemia – Hear No Evil? J Am Coll Cardiol 2017;69:1909-1912. Editorial
27. Sardar MR, **Aronow HD**. Vascular complications in transcatheter aortic valve replacement. Vasc Med 2017;22:234-244. Review.

28. Kolte D, Abbott JD, **Aronow HD**. Interventional Therapies for Heart Failure in Older Adults. *Heart Fail Clin* 2017;13:535-70. Review.
29. Goldsweig AM, **Aronow HD**. Novel Strategies to Reduce Femoropopliteal Restenosis: Low-Dose Paclitaxel-Coated Balloons and Paclitaxel-Coated Balloons Plus Stenting. *Circulation* 2017;135:2237-2240. Editorial.
30. Klein AJ, Jaff MR, Gray BH, **Aronow HD**, Bersin RM, Diaz-Sandoval LJ, Dieter RS, Drachman D, Feldman DN, Gigliotti OS, Gupta K, Parikh SA, Pinto DS, Shishehbor MH, White CJ. SCAI Appropriate Use Criteria for Peripheral Arterial Interventions: An Update. *Catheter Cardiovasc Interv* 2017;90:E90-E110. Guideline.
31. Kolte D, **Aronow HD**. The American Board of Vascular Medicine Endovascular Board Examination - Raising the bar by testing the test. *Vasc Med* 2017;22:343-344. Editorial.
32. Kolte D, **Aronow HD**, Abbott JD. Non-inferiority trials in interventional cardiology. *Circ Cardiovasc Interv* 2017 [published online August 8, 2017]. <https://doi.org/10.1161/CIRCINTERVENTIONS.117.005760>. Editorial
33. Feldman DN, Armstrong EJ, **Aronow HD**, Gigliotti OS, Jaff MR, Klein AJ, Parikh SA, Prasad A, Rosenfield K, Shishehbor MH, Swaminathan RV and White CJ. SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions. *Catheter Cardiovasc Interv*. 2018. Guideline.
34. Shishehbor MH, Jaff MR, Beckman JA, Misra S, Schneider PA, Lookstein R, Kashyap VS, **Aronow HD**, Schuyler Jones W and White CJ. Public Health Impact of the Centers for Medicare and Medicaid Services Decision on Pass-Through Add-On Payments for Drug-Coated Balloons: A Call to Action. *JACC Cardiovasc Interv*. 2018;11:496-499. Editorial.
35. Magnani JW, Mujahid MS, **Aronow HD**, Cene CW, Dickson VV, Havranek E, Morgenstern LB, Paasche-Orlow MK, Pollak A, Willey JZ, American Heart Association Council on E, Prevention, Council on Cardiovascular Disease in the Y, Council on C, Stroke N, Council on Peripheral Vascular D, Council on Quality of C, Outcomes R and Stroke C. Health Literacy and Cardiovascular Disease: Fundamental Relevance to Primary and Secondary Prevention: A Scientific Statement From the American Heart Association. *Circulation*. 2018;138:e48-e74. Scientific Statement.
36. Hawkins BM **Aronow HD**, Parikh SA, Rosenfield K, Naidu SS. SCAI 2018 Think Tank Proceedings: "What skillsets are required of vascular interventional cardiologists in evaluating and managing critical limb ischemia (CLI)? What role should SCAI play in supporting interventional cardiologists in their CLI practices, individually and collectively?" *Catheter Cardiovasc Interv* 2019;93:911-13. Conference proceeding.
37. Bailey SR, Beckan JA, Dao TD, Misra S, Sobieszczyk PS, White CJ, Wann LS, Bailey SR, Dao T, **Aronow HD**, Fazel R, Gornik HL, Gray BH, Halperin JL, Hirsch AT, Jaff MR, Krishnamurthy V, Parikh SA, Reed AB, Shamoun F, Shugart RE, Yucel EK. ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention: A Report of the American College of Cardiology Appropriate Use Criteria

Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine. *J Am Coll Cardiol* 2019;**73**(2): 214-237. Guideline.

38. The evolving role of transcatheter repair of ventricular septal rupture. Goldsweig AM, **Aronow HD**. *Cardiology* 2018;141:233-235. Editorial.
39. Kolte D, Parikh SA, Piazza G, Shishehbor MH, Beckman JA, White CJ, Jaff MR, Iribarne A, Nguyen TC, Froehlich JB, Rosenfield K, **Aronow HD**. Vascular Teams in Peripheral Vascular Disease. *J Am Coll Cardiol* 2019;73:2477-86. ACC Peripheral Vascular Disease Council Perspective.
40. Misra S, Shishehbor MH, Takahashi EA, **Aronow HD**, Brewster LP, Bunte MC, Kim ESH, Rich K. Perfusion Assessment in Critical Limb Ischemia: Principles for Understanding and the Development of Evidence and Evaluation of Devices. *Circulation*. 2019;140:e657-e672. AHA Scientific Statement.
41. Anderson HV, Bersin RM, Abbott JD, **Aronow HD**, Bass TA, Brilakis ES, Cavaye DM, Cohen MG, Dean LS, Dippel E, Garratt KN, Greenbaum AB, Hanzel GS, Helmy T, Lerman A, Magd AA, Marshall JJ, Medigo A, Mooney MR, Naidu SS, O'Neill B, Pichard AD, Rinaldi MJ, Sorajja P, Szerlip M, Wood DA, Zidar JP; the IAGS Writing Group. Clinical Conference Proceedings: 15th Biennial International Andreas Gruentzig Society Meeting. *J Interv Cardiol* 2019;31:98-132.
42. Kolte D, **Aronow HD**, Kennedy KF and Ehsan A. Analysis of administrative claims data provides valid and meaningful conclusions despite its imperfections. *J Thorac Cardiovasc Surg*. 2019 (DOI 10.1016/j.jtcvs.2019.05.026). Letter.
43. Sardar P, Abbott JD, Kundu A, **Aronow HD**, Granada JF and Giri J. Impact of Artificial Intelligence on Interventional Cardiology: From Decision-Making Aid to Advanced Interventional Procedure Assistance. *JACC Cardiovasc Interv*. 2019;12:1293-1303. Review.
44. Naidu SS, Daniels MJ, Elmariah S, Garcia S, Klein AJ, Feldman DN, Ing FF, Kavinsky CJ, Devireddy C, Mahmud E, Grines CL, Henry TD, Duffy PL, Amin ZC, **Aronow HD**, Banerjee S, Brilakis ES, Herrmann HC, Hijazi ZM, Jaffer FA, Latif F, Messenger JC, Parikh SA, Poulin MF, Reilly JP, Rosenfield K, Szerlip M, Vincent RN, Cox DA, And the members of the STTC, Baker D, Bhalla N, Bowen R, Camp C, Govender D, Haggstrom K, Hargus N, Hite D, Meikle J, Mylor B, Pierce V, Prince B, Roach J, Rudy J, Schludi B, Struck J, Tochterman A, Tolve M, William DM and Yowe S. Hot topics in interventional cardiology: Proceedings from the Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Think Tank. *Catheter Cardiovasc Interv*. 2019;94:598-606. Conference Proceedings.
45. **Aronow HD** and Bavishi C. Mechanical Complications in Acute Myocardial Infarction: Awaiting an Ounce of Prevention. *JACC Cardiovasc Interv*. 2019;12:1837-1839. Editorial.

46. Goldsweig AM, **Aronow HD**. Identifying Patients Likely to be Readmitted After Transcatheter Aortic Valve Replacement. *Heart* 2019 [*in press*]. Review.
47. Velagapudi P, Asawaer M, Goldsweig A, Alenezi F, Chatzizisis Y, **Aronow HD**, Abbott JD. Mechanisms of stent failure: Lessons from IVUS and OCT. *Curr Cardiovasc Imaging Rep* 2019;12:35 [*in press*]. Review.
48. Kolluri R, **Aronow H**, Gornik H, Weinberg I and Ratchford E. Message from your Executive Leadership. *Vasc Med* 2019 [online before print] DOI 10.1177/1358863X19894646.
49. Szerlip M, Feldman DN, **Aronow HD**, Blankenship JC, Choi JW, Elgendy IY, Elmariah S, Garcia S, Goldstein BH, Herrmann H, Hira RS, Jaff MR, Kalra A, Kaluski E, Kavinsky CJ, Kolansky DM, Kong DF, Messenger JC, Mukherjee D, Patel RAG, Piana R, Senerth E, Shishebor M, Singh G, Singh V, Yadav PK and Cox D. SCAI publications committee manual of standard operating procedures. *Catheter Cardiovasc Interv*. 2020. DOI 10.1002/ccd.28754. *Scientific Statement*.
50. Sardar P and **Aronow HD**. Renal denervation for hypertension: we've come a long way! *Cardiovasc Diagn Ther*. 2019;9:607-608. DOI 10.21037/cdt.2019.09.15. *Editorial*.
51. **Aronow, HD** and M. Saad. Femoropopliteal Drug-Eluting Versus Bare-Metal Stents: Lost a BATTLE, But Not the War! *JACC Cardiovasc Interv* 2020;13:458-460. DOI 10.1016/j.jcin.2019.12.030. *Editorial*.
52. Szerlip M, Anwaruddin S, **Aronow HD**, Cohen MG, Daniels MJ, Dehghani P, Drachman DE, Elmariah S, Feldman DN, Garcia S, Giri J, Kaul P, Kapur N, Kumbhani DJ, Meraj PM, Morray B, Nayak KR, Parikh SA, Sakhuja R, Schussler JM, Seto A, Shah B, Swaminathan RV, Zidar DA and Naidu SS. Considerations for Cardiac Catheterization Laboratory Procedures During the COVID-19 Pandemic Perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (SCAI ELM) Members and Graduates. *Catheter Cardiovasc Interv* 2020. DOI 10.1002/ccd.28887. *Perspective*
53. Welt FGP, Shah PB, **Aronow HD**, Bortnick AE, Henry TD, Sherwood MW, Young MN, Davidson LJ, Kadavath S, Mahmud E, Kirtane AJ, American College of Cardiology's Interventional C, the Society of Cardiovascular A and Intervention. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From ACC's Interventional Council and SCAI. *J Am Coll Cardiol* 2020. DOI 10.1016/j.jacc.2020.03.021. *Council Perspective*.
54. **Aronow HD**. Message from the Scientific Program Committee Chair. *Vasc Med*. 2020 [*in press*]
55. **Aronow HD**. Peripheral Vascular Intervention from Head to Toe: Navigating the Turns. *Interv Cardiol Clin*. 2020;9:ix-x. DOI 10.1016/j.iccl.2020.01.001. *Editorial*.

56. Henien S, **Aronow HD** and Abbott JD. Quality management in the cardiac catheterization laboratory. *J Thorac Dis.* 2020;12:1695-1705.
57. Feldman DN, Armstrong EJ, **Aronow HD**, Banerjee S, Diaz-Sandoval LJ, Jaff MR, Jayasuriya S, Khan SU, Klein AJ, Parikh SA, Rosenfield K, Shishehbor MH, Swaminathan RV and White CJ. SCAI guidelines on device selection in Aorto-Iliac arterial interventions. *Catheter Cardiovasc Interv.* 2020. *Guideline*

#### Books And Book Chapters

1. **Aronow HD**, Topol EJ: Detection of vulnerable plaque. In Topol EJ (ed): Textbook of Interventional Cardiology. Philadelphia, PA. W.B. Saunders, 2002, pp. 1063-87. Book chapter.
2. **Aronow HD**, Topol EJ: Antiplatelet therapy in cardiology. In Gresele P, Page PC, Fuster V, Vermylen J (eds): Platelets in thrombotic and non-thrombotic disorders: pathophysiology, pharmacology and therapeutics. New York, NY. Cambridge University Press, 2002, pp. 1013-1039. Book chapter
3. **Aronow HD**, Topol EJ: Identifying the vulnerable plaque and the vulnerable patient. In Theroux P (ed): Acute coronary syndromes: A Companion to Braunwald's Heart Disease. Philadelphia, PA. Harcourt Health, 2003, pp. 661-676. Book chapter.
4. **Aronow HD**, Ouriel K. "Management of Complications: Surgical and Endovascular Approaches" In Casserly I, Sachar R, Yadav J (eds): Manual of Peripheral Vascular Intervention. Lippincott Williams & Wilkins 2005. Philadelphia, PA, 2005. Book chapter.
5. Mejia V, **Aronow HD**: "Lipid-lowering therapy" In Mukherjee D (ed): Pharmacological Therapies for Peripheral Vascular Diseases. London, UK. Martin Dunitz, 2005. Book chapter.
6. Mejia VM, **Aronow HD**: "Percutaneous Interventional Management of Renal Vascular Disease" In Mohler ER, Townsend RR (eds): Advanced Therapy in Hypertension and Vascular Disease. Hamilton, Ontario. BC Decker, 2006. Book chapter
7. Sharma AM, **Aronow HD**. (2012). Lower Extremity Peripheral Arterial Disease, Traditional and Novel Risk Factors in Atherothrombosis, Dr. Efrain Gaxiola (ed), ISBN: 978-953-51-0561-9, InTech, Available from: <http://www.intechopen.com/books/traditional-and-novel-risk-factors-in-atherothrombosis/lower-extremity-peripheral-arterial-disease>. Book Chapter.
8. Sharma AM, **Aronow HD**. (2013). Management of carotid artery disease in the setting of coronary artery disease in need of bypass surgery, Dr. Wilbert S. Aronow (ed), ISBN: 978-953-51-1025-5, InTech, Available from: <http://dx.doi.org/10.5772/55669>. Book Chapter.
9. Wayangankar SA, **Aronow HD**. "Carotid artery stenting: Operator and institutional learning curves." In White CJ, Rosenfield KR (eds): Carotid and Cerebrovascular Disease, An Issue of Interventional Cardiology Clinics, ISBN: 978-0323263962, Philadelphia, PA. Elsevier, 2013. Book Chapter.

10. Goldsweig AM, **Aronow HD**. CathSAP 5: Carotid Artery Interventions – Endarterectomy, Stenting, and Neuroprotection. *Release date 6/7/17*. Invited Chapter.
11. Goldsweig AM, **Aronow HD**: “History of Endovascular Intervention, Fluoroscopy, Basics of Angiography, Contrast, Patient Selection, and Informed Consent” In Mena C, Jayasuriya S (eds): Peripheral Vascular Disease: A Clinical Approach. Philadelphia, Pennsylvania. Wolters Kluwer, 2018. Book Chapter.
12. Kolte D, **Aronow HD**. “Multidisciplinary Team Approach in Endovascular Intervention (Including Hybrid Revascularization)” In Mena C, Jayasuriya S (eds): Peripheral Vascular Disease: A Clinical Approach. Philadelphia, Pennsylvania. Wolters Kluwer, 2018. Book Chapter.

#### Other Non-Peer-Reviewed Publications

1. **Aronow HD**. Stent-or-bypass dilemma revisited. Health News 2001;7:1-2. Review.
2. **Aronow HD**. Man Versus Machine: Are carotid stent simulators ready for education and certification? Endovascular Today, October 2005. Editorial/Cover Story.
3. **Aronow HD**. Recognizing Peripheral Arterial Disease: A case report. eMedicine.com. September 18, 2006. Case report.
4. **Aronow HD**. A World Without CAS PMS Studies: What will the CAS landscape look like without CAS postmarket surveillance studies, and what will it mean for our patients? Endovascular Today, September 2013. Editorial/Cover Story.

#### Publications in Preparation

1. Schmidt T, Kennedy KF, Gurm HS, Seth M, Abbott JD, Carson J, Louis DW, Mamdani S, **Aronow, HD**. The Blue Cross Blue Shield of Michigan Cardiovascular Consortium Transfusion Risk Model: Validation and Assessment of Effectiveness for Transfusion Prevention in Transradial PCI .
2. Flood SP, Kennedy, KF, Louis DW, Abbott JD, Mamdani S, **Aronow HD**. Validation of CathPCI Bleeding Model in Transradial vs Transfemoral PCI Patients.
3. Apostolidou E, Kolte D, Kennedy KF, Beale CE, Abbott DJ, Ehsan A, Gurm H, Carson J, Mamdani S, **Aronow HD**. Hospital transfusion culture independently predicts likelihood of transfusion following inpatient cardiovascular procedures.
4. Lam M, Kolte D, Kennedy K, Naidu S, Feldman D, Chu A, **Aronow H**. Incidence, timing and predictors of permanent pacemaker placement following alcohol septal ablation for hypertrophic cardiomyopathy

#### ABSTRACTS



1. **Aronow HD**, Eagle KA, Muller DWM, Bates ER, Werns SW, Kline-Rogers E, Karavite D, Cao N, Moscucci M. Application of critical pathways in the evaluation of new medical technology: the intracoronary stent as a model. *J Am Coll Cardiol.* 1998; 31:50A.
2. **Aronow HD**, Peyser PA, Eagle KA, Russman PL, Krum M, Harris K, Moscucci M. Length of stay predictors following coronary artery stenting. *J Am Coll Cardiol.* 1999;33:75A.
3. **Aronow HD**, L'Allier PL, Yadav JS, Schneider JP, Topol EJ, Ellis SG. Does abciximab cause excess bleeding when combined with clopidogrel for coronary artery stenting? *Can J Cardiol* 1999;15:221D.
4. L'Allier PL, **Aronow HD**, Yadav JS, Schneider JP, Topol EJ, Ellis SG. Clopidogrel is a safe and effective adjunctive anti-platelet therapy for coronary artery stenting. *Can J Cardiol* 1999;15:137D.
5. L'Allier P, **Aronow H**, Yadav J, Schneider J, Topol E, Ellis S. "Is clopidogrel a safe and effective adjunctive anti-platelet therapy for coronary artery stenting." *J Am Coll Cardiol* 1999;33:40A.
6. L'Allier PL, **Aronow HD**, Cura FA, Bhatt DL, Albirini A, Schneider JP, Topol EJ, Ellis SG. Short term mortality lower with clopidogrel than ticlopidine following coronary artery stenting. *J Am Coll Cardiol.* 2000;35:66A.
7. **Aronow HD**, Roe MT, Lauer MS, Houghtaling PS, Lincoff AM, Harrington RA, Califf RM, Topol EJ. Early and striking mortality reduction after acute coronary syndromes following lipid lowering therapy. *J Am Coll Cardiol.* 2000; 35:411A.
8. Chew DP, Robbins MA, **Aronow HD**, Bhatt DL, Roffi M, Schneider JP, Ellis SG. Baseline CRP predicts 30-day death and myocardial infarction following PCI. *Circulation* 2000;102:II-735.
9. **Aronow HD**, Wolski KE, Lauer MS. Marked reduction in mortality with early lipid-lowering therapy after ST and non-ST elevation acute coronary syndromes. *Circulation* 2000;102:II-435.
10. **Aronow HD**, Houghtaling PL, Wolski KE, Topol EJ, Lauer MS. Stunning reduction in death and myocardial infarction observed with early lipid lowering therapy after acute coronary syndromes. *J Am Coll Cardiol.* 2001;37:648A.
11. **Aronow HD**, Novaro GM, Prosper DM, Lincoff AM, Topol EJ, Nissen SE. Initiation of lipid-lowering therapy during hospitalization for coronary intervention is a powerful predictor of subsequent compliance. *Eur Heart J* 2001;22:271.
12. Casserly IP, **Aronow HD**, Popovich J, Nissen SE, Tuzcu EM. Lack of relationship between circumferential distribution of atheroma burden and neointimal growth. *Circulation* 2001;104:II-775.

13. **Aronow HD**, Novaro GM, Houghtaling PL, Lauer MS. The CABG paradox: CABG patients are least likely to receive lipid-lowering therapy at discharge. *Circulation* 2001;104:II-790.
14. Sprecher D. L., Foody J. M., Acevedo M., Scafidi K. M., **Aronow H.**, Pearce, G. L. Dietary intervention with orange juice lowers blood pressure: pilot study. *J Am Coll Cardiol* 2002;39:254A.
15. **Aronow HD**, McRae AT, Quinn MJ, Topol EJ, Lincoff AM, Houghtaling PL, Lauer MS. Patients on lipid-lowering therapy at the time of a myocardial infarction have smaller infarcts: further evidence to suggest a salutary effect in acute coronary syndromes. *J Am Coll Cardiol* 2002;39:318A.
16. **Aronow HD**, Quinn MJ, Gurm HS, Topol EJ, Lincoff AM, Brennan DM, Lauer, MS. Myocardial necrosis is halved in patients undergoing elective percutaneous coronary intervention who are pre-treated with lipid-lowering therapy. *J Am Coll Cardiol* 2002;39:32A.
17. **Aronow HD**, Shishehbor MH, Whitlow PL, Davis DA, Bhatt DL, Topol EJ, Bajzer C, Yadav JS. White blood cell count predicts microembolic Doppler signals during carotid stenting: a link between inflammation and embolization. *Eur Heart J* 2002;23:129.
18. Cho L, Chew DP, Roffi M, Moliterno DJ, Reginelli J, **Aronow H**, Chan A, Quinn M, Gum P, Lincoff AM. Bivalrudin appears to be safe and efficacious with GP IIb/IIIa inhibitors. *Circulation* 2002;106:II-494.
19. **Aronow HD**, Shishebor MH, Davis DA, Bhatt DL, Roffi M, Cho L, Agah R, Chan AW, Whitlow PL, Bajzer C, Yadav JS. White blood cell count predicts microembolic Doppler signals during carotid stenting: A link between inflammation and embolization. *Circulation* 2002;106:II-577.
20. Ghanamah M, Reginelli JP, **Aronow HD**, Askari AT, Chew DP, Bhatt DL. Renal insufficiency in the setting of an acute coronary syndrome is associated with a marked increase in death and myocardial infarction at 30 days. *J Am Coll Cardiol* 2003;41:375A.
21. Casserly IP, Casserly LF, **Aronow HD**, Reginelli J, Sachar R, Exaire C, Dauterman KW, Tuzcu EM, Moliterno DJ, Bhatt DL, Ellis SG. Diabetes is an independent predictor of increased mortality following contemporary percutaneous coronary intervention for proximal left anterior descending artery disease. *J Am Coll Cardiol* 2003;41:28A.
22. Gurm HS, **Aronow HD**, Askari AT, Brennan D, Lincoff AM, Topol AJ. Renal insufficiency and anemia in patients undergoing percutaneous coronary interventions: A double jeopardy. *J Am Coll Cardiol* 2003;41:11A.
23. Reginelli JP, Ghanamah M, Chew DP, Gurm H, Casserly IP, **Aronow HD**, Bhatt DL, Ellis SG. Impact of the prediabetic state on long-term outcomes following percutaneous coronary intervention. *J Am Coll Cardiol* 2003;41:11A.

24. Zidar FJ, Quinn MJ, Bhatt DL, Vivekananthan DP, **Aronow HD**, Ellis SG, Plow E, Topol EJ. Clopidogrel pretreatment reduces platelet inflammatory marker expression in patients undergoing percutaneous coronary intervention. *J Am Coll Cardiol* 2003;41:45A.
25. **Aronow HD**, Quinn MJ, Gurm HS, Lauer MS, Brennan DM, Topol EJ, Lincoff AM. Pre-procedure inflammatory state predicts peri-procedural myocardial infarction after elective percutaneous coronary intervention: An EPIC substudy. *J Am Coll Cardiol* 2003;41:17A.
26. Sachar R, **Aronow HD**, Reginelli JP, Casserly IP, Dauterman KW, Gum P, Bajzer C, Bhatt DL, Yadav JS. Common carotid artery disease in high risk patients: Is stenting the treatment of choice? *Am J Cardiol* 2003;92:121L.
27. **Aronow HD**, Casserly IP, Shishehbor MH, Sachar R, Bajzer CT, Bhatt DL, Yadav JS. Patients with prior acute coronary and neurological ischemic syndromes are at high risk for early ischemic events following carotid stenting: A link between prior and future pan-vascular vulnerability. *Am J Cardiol* 2003;92:51L.
28. **Aronow HD**, Califf RM, Harrington RA, Vallee M, Graffagnino C, Shuaib A, Fitzgerald D, Easton JD, Van de Werf F, Diener HC, Ferguson J, Koudstaal P, Amarenco P, Theroux P, Davis S, Topol EJ. Higher aspirin dose is associated with reduced mortality and more serious bleeding in patients with recent cerebrovascular or coronary ischemic events: Insights from the BRAVO trial. *Circulation* 2003;108:IV-680-81.
29. **Aronow HD**, Shishehbor MH, Gum P, Sachar R, Bajzer CT, Yadav JS. Predictors of late mortality following carotid stenting in high-risk patients. *Circulation* 2003;108:IV-687.
30. Steinhubl SR, **Aronow H**, Brennan DM, McErlean E, Topol EJ. Clinical predictors of major atherothrombotic events 1 year following elective PCI: Insights from the CREDO trial. *Circulation* 2003;108:IV-457.
31. Sachar R, **Aronow HD**, Casserly IP, Sheikh M, Kapadia S, Bhatt DL, Bajzer C, Yadav JS. Inaccuracy of Doppler ultrasonography for assessing restenosis after internal carotid artery stenting. *J Am Coll Cardiol* 2004;43:91A.
32. **Aronow HD**, Steinhubl SR, Brennan DM, Topol EJ. Long-term clopidogrel therapy following percutaneous coronary intervention improves clinical outcome but is not associated with increased bleeding: New insights from the CREDO trial. *J Am Coll Cardiol* 2004;43:21A.
33. **Aronow HD**, Samaha RS, Kimmel SE, Williams M, Roche D, Lauer MS. Increasing statin dose is associated with a stepwise decline in long-term all-cause mortality. Presented at the American Heart Association Scientific Sessions 2004.
34. **Aronow HD**, Samaha FF, Weiner M, Kimmel SE, Williams M, Roche D, Jacobs P, Lauer MS. Higher statin dose is associated with lower all-cause mortality: Evidence for a dose-response relationship in primary prevention. *J Am Coll Cardiol* 2005;391A.

35. Moscucci M, Smith DE, **Aronow HD**, Gardin J, Riba A, Safian R, Changezi H, Share D. The Critical Role of a Weight and Creatinine Adjusted Contrast Dose on Fatal and Non-Fatal Adverse Outcomes on Percutaneous Coronary Intervention. *Circulation* 2006;114:II-841.
36. Moscucci M, Smith DE, D'Haem C, Patel K, LaLonde T, Khanal S, **Aronow HD**, Riba A, Safian R, Share D. The Effect of Bivalirudin on Bleeding Risk in Patients with Chronic Renal Failure Undergoing Contemporary Percutaneous Coronary Intervention (PCI): an Analysis From a Large Multicenter PCI Registry. *Circulation* 2006;114:II-862.
37. **Aronow HD**, Donohoe D, Buchbinder M, Eskandari M, Krol K, Zidar J, Bajwa T, Bacharach JM, Wang H. Defining the High Endovascular Risk Patient with Carotid Stenosis: Insights from the Cordis Carotid Stent Collaborative. *Am J Cardiol* 2007;100:88L.
38. **Aronow HD**, Glaser R, Selzer F, Abbott JD, Williams DO, Shapiro TA, Kip KE. Higher Clopidogrel Loading Dose is Associated With Less Frequent Ischemic Complications Following PCI: Insights from the NHLBI Dynamic Registry. *Circulation* 2007;116:II-517.
39. **Aronow HD**, Smith D, O'Donnell MJ, McNamara R, Riba A, Changezi H, Kline-Rogers E, Share D, Moscucci M. Frequency and Predictors of Clopidogrel Pre-treatment in Patients Undergoing Percutaneous Coronary Intervention: A Report From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium PCI Registry. *J Am Coll Cardiol* 2008;51:B85.
40. **Aronow HD**, Glaser R, Selzer F, Abbott JD, Williams DO, Shapiro TA, Kip KE, Kelsey SF. Underutilization of Clopidogrel Pre-treatment in the NHLBI Dynamic PCI Registry: A Missed Opportunity? *J Am Coll Cardiol* 2008;51:B85.
41. **Aronow HD**, Donohoe D, Safian R, Raabe R, Nicholas J, Boxberger G, Hull J, Solis M, Shindelman L, Wang H. Predictors of Cardiac Death or MI Following Carotid Stenting: Insights from the Cordis Carotid Stent Collaborative. *J Am Coll Cardiol* 2008;51:B74.
42. **Aronow HD**, Donohoe D, Queral L, Andriole J, Leya F, Weatherford D, Hibbard R, Laird JR, Altschuler J, Wang H. Identifying the High Endovascular Risk Patient with Carotid Stenosis: An analysis from the Cordis Carotid Stent Collaborative. *J Am Coll Cardiol* 2008;51:B75.
43. Grossman PM, Munir K, Gurm H, Chetcuti S, **Aronow H**, Kassab E, Karve M, Nino C, Dunning D, Moscucci M. Temporal Trends in Peripheral Arterial Interventions: Legs Up, Renals Down. *Circulation* 2008;118:S1079.
44. Gualano SK, Share D, **Aronow H**, LaLonde T, Changezi H, McNamara R, Smith D, Moscucci M. Declining Use of Drug Eluting Stents for Approved and Off-Label Indications. *Circulation* 2008;118:S901.
45. Grossman PM, Munir K, Gurm HS, Bove PG, Wang SK, Fox JM, **Aronow HD**, Nypaver TJ, Riba A, Share D, Moscucci M. Contrast-induced nephropathy in patients undergoing peripheral vascular intervention: incidence, risk factors and outcomes. *J Am Coll Cardiol* 2009;53:A85.

46. **Aronow HD**, Hess G, Hill J, Kuznik A, Liu LZ. The association between switching from atorvastatin to simvastatin and LDL goal attainment in the secondary prevention setting. *J Am Coll Cardiol* 2009;53:A206.
47. **Aronow HD**, Wang H, Yadav JS, Ouriel K, Katzen BT, Kwolek CJ, Cohen S. Incidence, predictors and prognostic significance of peri-procedural transient ischemic attack associated with carotid stenting: Observations from the Cordis Carotid Stent Collaborative. *J Am Coll Cardiol* 2009;53:A87.
48. **Aronow HD**, Steinhubl SR, Tang WHW, Brennan D, Wilensky RL, Marso SP, Wegner M, Topol EJ. Lipoprotein-associated Phospholipase A2 predicts 28-day and 1-year adverse events following PCI: A CREDO substudy. *J Am Coll Cardiol* 2009;53:A48.
49. Sharma AM, Toram S, Hubbard B, **Aronow HD**. Myocardial infarction: An extremely rare complication of foam sclerotherapy. *Journal of General Internal Medicine* 2009;24(supplement 1):S335.
50. Grossman PM, Kasapis C, Munir K, Share D, Chetcuti SJ, Nypaver TJ, Bove P, **Aronow HD**, Gurm HS. Contemporary Below-the-Knee and Femoral-Popliteal Percutaneous Arterial Intervention: A Comparison of Procedural Outcomes and Predictors of Success - Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2 -PVI). *Circulation* 2009;120:S956-S957.
51. Grossman PM, Kaufman SR, Share D, **Aronow HD**, Chetcuti SJ, Bove P, Nypaver TJ, Fox JM, Mansour MA, Gurm HS. Does location matter? Improvement in quality of life for patients undergoing percutaneous vascular interventions, insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. *J Am Coll Cardiol* 2010; 2010;55;A180.E1689.
52. **Aronow HD**, Tang WHW, Steinhubl S, Brennan D, Wilensky R, Marso S, Berger P, Wegner M, Topol E, Predictors of lipoprotein-associated phospholipase A2 mass and activity levels among patients with stable and acute coronary syndromes: A CREDO biomarker substudy. *J Am Coll Cardiol* 2010; 2010;55;A187.E1753.
53. The changing definition of contrast induced nephropathy and its clinical implications: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Slocum N, Moscucci M, Smith D, **Aronow H**, Dixon S, Share D, Gurm HS. *J Am Coll Cardiol* 2010;55;A142.E1334.
54. Do the Right Thing: Dramatic Impact of Risk Factor Control in Patients with Claudication Presenting for Peripheral Vascular Interventions. Ardati AK, Kaufman SR, Gurm HS, **Aronow HD**, Nypaver TJ, Bove PG, Grossman PA. *Circulation* 2010;122:A11406.
55. Rabbani AB, Smith DE, Moscucci M, **Aronow H**, Ruwende C, Naoum J, Share D, Gurm HS. Trends, Determinants, and Implications of Nephropathy Associated with Primary PCI. *Circulation* 2010;122:A12683.
56. Cohen DJ, Stolker JM, Clark WM, Mahoney EM, Wang K, Demaerschalk BM, Sam, AD, Elmore JR, Weaver FA, **Aronow HD**, Goldstein LB, Howard G and Brott TG, for the CREST

Investigators. Health-Related Quality of Life after Carotid Stenting versus Carotid Endarterectomy: Results from the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). *Stroke* 2011;42:E78.

57. **Aronow HD**, Munir K, Schreiber TL, Davis TP, Bove PG, Nypaver TJ, Grossman PM. Predictors of Six Month Repeat Revascularization following Peripheral Vascular Intervention: Observations from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. *J Am Coll Cardiol* 2011;57:1668.
58. Opina MT, Singal B, Cowen M, Robinson E, **Aronow HD**. Association between intravenous low dose unfractionated heparin plus eptifibatid versus bivalirudin on bleeding following percutaneous coronary intervention. Presented at 2011 St. Joseph Mercy Hospital Resident Research Forum. Ann Arbor, MI.
59. Wayangankar SA, Abu-Fadel M, **Aronow H**, Kennedy K, Gupta R, Gray W, Rosenfield K, Hennebry T. Hemorrhagic and Ischemic Outcomes Following Bivalirudin vs Unfractionated Heparin during Carotid Artery Stenting: Analysis from the NCDR® *J Am Coll Cardiol* 2012;59:E255.
60. Muthappan P, Smith D, **Aronow H**, Eagle K, Wohns D, Fox J, Share D, Gurm H. The epidemiology and outcomes of percutaneous coronary intervention before high risk non-cardiac surgery: Insights from the BMC2 registry. *J Am Coll Cardiol* 2012;59:E339.
61. Kenaan M, Seth M, **Aronow H**, Wohns D, Dixon S, Share D, Gurm H. Lack of aspirin use prior to PCI is relatively common and strongly associated with increased in-hospital mortality. *J Am Coll Cardiol*. 2013;61(10\_S).
62. Renard B, Seth M, Share D, **Aronow H**, Henke P, Gurm H, Grossman P. The power of a proceduralist: Prescribing guideline-based medical therapy prior to hospital discharge increases compliance at six months in patients with severe peripheral artery disease. *J Am Coll Cardiol*. 2013;61(10\_S).
63. Jalbert JJ, Nguyen LL, Gerhard-Herman MD, Jaff MR, Seeger JD, Kumamaru H, Williams LA, Liu J, Chen CY, Johnston JA, **Aronow HD**, Setoguchi S. 30-Day mortality after carotid artery stenting (CAS) in trial versus real-world settings. *Stroke* 2014;45:A83.
64. Bagai A, Chaitman BR, Gosselin G, Shah BN; Diaz A, Humen D, Banerjee S, Perna GP, Schuchlenz H, Cheema AN, Wu Y, Kronenberg MW, **Aronow HD**, Miller TD, Hajjar ME, Druz T, Pracon R, Newby LK, Alexander K, Goodman S; Bangalore S; Maron DJ; Hochman JS, Mahaffey KW. Substantial variability between laboratories in troponin decision level for diagnosis of myocardial infarction and assay 99<sup>th</sup> percentile: Findings from the international study of comparative health effectiveness with medical and invasive approaches (ISCHEMIA) trial. *J Am Coll Cardiol*. 2014;63(12\_S).
65. Grossman PM, Park YJ, Boros MJ, Nypaver TJ, **Aronow H**, Schreiber T, Henke P, Gurm HS. The deleterious implications of contrast induced nephropathy in patients undergoing peripheral vascular intervention: Observations from the Blue Cross Blue Shield of Michigan

Cardiovascular Consortium Vascular Interventions Collaborative (BMC2 VIC). *J Am Coll Cardiol*. 2014;64(11\_S).

66. Jalbert JJ, Nguyen LL, Gerhard-Herman MD, Williams LA, Chen C-Y, Liu J, Kumamaru H, Rothman AT, Jaff MR, Seeger JD, Benenati JF, Schneider PA, **Aronow HD**, Joshnston JA, Brott TG, Tsai TT, White CJ, Setoguchi S. Carotid artery stenting and carotid endarterectomy are comparable among Medicare beneficiaries treated in routine clinical practice. *Circulation* 2014;130:A14735.
67. Jalbert JJ, Nguyen LL, Gerhard-Herman MD, Williams LA, Chen C-Y, Liu J, Kumamaru H, Rothman AT, Seeger JD, Benenati JF, Schneider PA, **Aronow HD**, Joshnston JA, Tsai TT, White CJ, Setoguchi S. Potential heterogeneity in the performance of carotid artery stenting relative to carotid endarterectomy among subgroups of Medicare beneficiaries in routine clinical practice. *Circulation* 2014;130:A14764.
68. Omran J, Obai A, Firwana B, Hawkins B, Abu-Fadel M, White C, Gray WA, **Aronow H**, Al-Dadah, A. Surgical versus Endovascular Treatment for Acute Limb Ischemia: A Systematic Review and Meta-Analysis of Clinical Trials. *J Am Coll Cardiol* 2015;66:B325.
69. Omran J, Abdullah O, Firwana B, Abu-Fadel M, White C, Gray WA, **Aronow H**, Al-Dadah A. Proximal Balloon Occlusion versus Distal Filter Protection in Carotid Artery Stenting: A Meta-Analysis of Clinical Trial Data. *J Am Coll Cardiol* 2015;66:B33.
70. Noyes AM, Abbott JD, Gosch K, Smolderen K, Spertus JA, Hyder O, Soukas PA, Shishehbor MH, **Aronow HD**. Association Between Patient Characteristics and Baseline Health Status Among an International Cohort of Claudicants: An Analysis From the Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT) Registry. *J Am Coll Cardiol* 2016;67:2263
71. Roumia M, **Aronow H**, Soukas P, Gosch K, Smolderen K, Spertus J, Abbott JD. Sex Differences in Disease Specific Health Status Measures in Patients with Symptomatic Peripheral Arterial Disease *J Am Coll Cardiol* 2016;67:2276
72. Kolte D, Sardar P, Khera S, Aronow W, Owan T, Jain D, Panza J, Frishman W, Fonarow G, Bhatt D, **Aronow H**, Abbott J. Culprit only versus multivessel percutaneous coronary intervention in patients with cardiogenic shock complicating acute myocardial infarction: A meta-analysis of observational studies. *J Am Coll Cardiol* 2016;67:102
73. Hammad TA, Jones PG, Smolderen KG, Spertus JA, Patel MR, **Aronow HD**, Shishehbor MH. The Majority of Patients Presenting With Symptomatic Peripheral Artery Disease Report Atypical Symptoms: Findings From the PORTRAIT Registry. *Circulation* 2016;134:A20116.
74. Johnston A, Jones WS, Gosch K, Patel M, Vemulapalli S, **Aronow H**, Abbott D, Shishebor. Association Between Ankle-Brachial Index Values, Symptom Classification, and PAD-Specific Health Status in Patients With Intermittent Claudication. *Circulation* 2016;134:A18159.

75. Roumia M, Kolte D, **Aronow H**, Soukas P, Smolderen K, Spertus J, Gosch K, Nolthenius RT. Sex Differences in Health Status Outcomes in Patients With Symptomatic PAD. *Circulation* 2016;134:A19959.
76. Kolte D, Roumia, M, Smolderen K, Wang J, Jones P, Spertus JA, Hiatt WR, Hirsch AT, **Aronow HD**, Soukas PA, Abbott JD. Factors Associated With Referral to Exercise Therapy in Patients With Peripheral Arterial Disease: Insights From the PORTRAIT Registry. *Circulation* 2016;134:A20126.
77. Velagapudi P, Turagam M, Parikh P, Kholte D, **Aronow H**, Abbott JD. "Very Early Vs. Delayed Revascularization In Non-ST Elevation Myocardial Infarction: A Meta-analysis Of Clinical Outcomes". CRT 2017. Washington, DC. February 2017.
78. Kolte D, Goldsweig A, Abbott JD, Gordon P, Sellke FW, Ehsan A, Sodha N, Sharaf B, **Aronow HD**. Infective endocarditis after transcatheter aortic valve replacement: insights from the Nationwide Readmissions Database. *J Am Coll Cardiol* Mar 2017, 69 (11 Supplement) 1308; DOI: 10.1016/S0735-1097(17)34697-1.
79. Kolte D, Shishehbor MH, Kennedy KF, Soukas P, Abbott JD, Drachman DE, Mamdani ST, Khera S, Hyder O, **Aronow HD**. Thirty-day readmissions following endovascular or surgical treatment for critical limb ischemia: analysis of the Nationwide Readmissions Database. *J Am Coll Cardiol* Mar 2017, 69 (11 Supplement) 2007; DOI: 10.1016/S0735-1097(17)35396-2.
80. Velagapudi P, Turagam M, Kolte D, Khera S, **Aronow H**, Leopold J, Abbott JD. Intramyocardial Autologous CD34+ Cell Therapy for Refractory Angina: A Meta-analysis. *J Am Coll Cardiol* Mar 2017, 69 (11 Supplement) 1064; DOI: 10.1016/S0735-1097(17)34453-4.
81. Velagapudi P, Turagam M, **Aronow H**, Khera S, Kolte D, Abbott JD. Angiography vs. Optical Coherence Tomography guided Percutaneous Coronary Intervention: A Meta-analysis of Clinical Outcomes. *J Am Coll Cardiol* Mar 2017, 69 (11 Supplement) 1113; DOI: 10.1016/S0735-1097(17)34502-3.
82. Goldsweig A, Wang Y, Forrest J, Cleman M, Minges K, Mangi A, **Aronow H**, Krumholz H, Curtis J. Ventricular Septal Rupture Complicating Acute Myocardial Infarction: Incidence, Treatment, and Outcomes Among Medicare Beneficiaries 1999-2014. *Catheter Cardiovasc Interv* 2017;89S2;S1.
83. Velagapudi P, Turagam M, Katta N, Khera S, Dhaval K, Heo S, Gordon P, **Aronow H**, Abbott DA. Cerebral Embolic Protection Device in Transcatheter Aortic Valve Replacement: An Updated Meta-Analysis of Randomized Controlled Trials. SCAI 2017 Scientific Sessions. New Orleans, LA; May 2017.
84. Kolte D, Khera S, Gupta T, Goldsweig A, Velagapudi P, Aronow WS, Tang G, Fonarow G, Bhatt DL, **Aronow HD**, Gordon PC, Sharaf B, Abbott JD. Association Between Hospital Transcatheter Aortic Valve Replacement Volume and 30-Day Readmissions. "Best of the Best" poster presentation at SCAI 2017 Scientific Sessions. *Catheter Cardiovasc Interv* 2017;89S2;S5-6.



85. Lima F, Kolte D, Kennedy K, Yen TY, Abbott JD, Soukas P, Hyder O, Mamdani ST, **Aronow HD**. Outcomes of Endovascular versus Surgical Revascularization for Chronic Mesenteric Ischemia: Insights from the National Inpatient Sample Database. "Best of the Best" poster presentation at SCAI 2017 Scientific Sessions. *Catheter Cardiovasc Interv* 2017;89S2;S10.
86. Gupta T, Khera S, Kolte D, Villablanca P, Goel K, Abbott JD, **Aronow HD**, Taub C, Fonarow GC, Rihal CS, Tang GH, Garcia MJ, Bhatt DL. Temporal Trends in Utilization and In-Hospital Outcomes of Transcatheter Aortic Valve Replacement in the United States. SCAI 2017 Scientific Sessions. New Orleans, LA; May 2017.
87. Goldsweig AM, Kennedy K, Kolte D, Abbott JD, Gordon PC, Sharaf BL, Sellke FW, Ehsan A, Sodha NR, **Aronow HD**. Predictors of Radiation Dosage in Transcatheter Aortic Valve Replacement" SCAI 2017 Scientific Sessions. New Orleans, LA; May 2017.
88. Louis DL, Pancholy S, Gordon P, Hyder O, Soukas P, Abbott JD, **Aronow HD**. Association Between Maximal ACT and Bleeding Complications During Transradial vs. Transfemoral PCI. SCAI 2017 Scientific Sessions. New Orleans, LA; May 2017.
89. Khera S, Villablanca P, Gupta T, Kolte D, Khan MH, Velagapudi P, **Aronow H**, Abbott JD, Rosenfield K, Drachman D, Bhatt D, Naidu S. Do Drug-eluting Stents Substantially Improve Long-Term Outcome in End-Stage Renal Disease? *Catheter Cardiovasc Interv* 2017;89S2;S162-3.
90. Lima F, Kolte D, Louis D, Kennedy K, Abbott JD, Soukas P, Hyder O, Mamdani S, **Aronow H**. Thirty-Day Readmissions After Endovascular or Surgical Revascularization for Chronic Mesenteric Ischemia: Insights from the National Readmissions Database. *J Am Coll Cardiol* Oct 2017, 70 (18 Supplement) B26-B27; DOI: 10.1016/j.jacc.2017.09.111.
91. Gupta T, Kolte D, Khera S, Goel K, Kalra A, Villablanca P, Bortnick A, **Aronow H**, Abbott JD, Fonarow G, Rihal C, Menegus M, Garcia M, Bhatt D. Association of Primary Insurance Status with Use of Revascularization and In-hospital Outcomes in Patients with Non-ST-segment Elevation Myocardial Infarction in the United States. *J Am Coll Cardiol* Oct 2017, 70 (18 Supplement) B177; DOI: 10.1016/j.jacc.2017.09.537.
92. Gupta T, Khera S, Kolte D, Goel K, Kalra A, Villablanca P, **Aronow H**, Abbott JD, Fonarow G, Elmariah S, Rihal C, Garcia M, Bhatt DL. Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Prior Coronary Artery Bypass Grafting: Trends in Utilization and a Propensity-Score Matched Analysis of In-hospital Outcomes. *J Am Coll Cardiol* Oct 2017, 70 (18 Supplement) B180-B181; DOI: 10.1016/j.jacc.2017.09.546.
93. Velagapudi P, Kolte D, Ather K, Khera S, Gupta T, Gordon P, **Aronow H**, Kirtane A, Abbott JD. Temporal Trends and Factors Associated With Prolonged Length of Stay in ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention. *J Am Coll Cardiol* Oct 2017, 70 (18 Supplement) B145; DOI: 10.1016/j.jacc.2017.09.443.

94. Bhardwaj B, Spertus J, Kennedy K, Jones S, Safley D, Tsai T, **Aronow H**, Vora A, Pokharel Y, Attaran RR, Feldman D, Salisbury A. Prevalence, predictors and outcomes of bleeding complications in peripheral vascular interventions for lower extremities: Insights from the NCDR PVI registry. *J Am Coll Cardiol* Oct 2017, 70 (18 Supplement) B25; DOI: 10.1016/j.jacc.2017.09.107.
95. Kolte D, Velagapudi P, Ather K, Khera S, Gupta T, Fonarow G, Bhatt D, **Aronow H**, Cohen D, Abbott JD. Length of Stay Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Association With 30-Day Readmissions and Implications for Healthcare Costs. *J Am Coll Cardiol* Oct 2017, 70 (18 Supplement) B133; DOI: 10.1016/j.jacc.2017.09.410.
96. Gray W, Shammam N, Pucillo A, Jenkins J, Garcia L, Davis T, **Aronow H**, Armstrong E, Zeller T, Scheinert D. Clinical outcomes and debris capture analysis using a novel filter during atherectomy: WISE LE study. *J Vasc Interv Radiol* 2018;29(2)e3.
97. Kolte D, Khera S, Vemulapalli S, Dai D, Heo S, Goldsweig A, **Aronow HD**, Elmariah S, Inglessis I, Palacios IF, Sharaf BL, Gordon, PC, Abbott JD. Outcomes Following Urgent/Emergent Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry. *J Am Coll Cardiol* Mar 2018, 71 (11 Supplement) A1009; DOI: 10.1016/S0735-1097(18)31550-X.
98. Chaudhry M, Kolte D, Saeed W, Khan A, Raza M, Qureshi R, Abbott JD, **Aronow HD**, Sardar M. Takotsubo Cardiomyopathy in Human Immunodeficiency Virus Positive Patients: National Inpatient Sample Based Retrospective Review. *J Am Coll Cardiol* Mar 2018, 71 (11 Supplement) A716; DOI: 10.1016/S0735-1097(18)31257-9.
99. Lima F, Kennedy KF, Kolte D, Abbott JD, Soukas PA, **Aronow HD**. Thirty-Day Readmissions After Carotid Artery Stenting and Endarterectomy: Insights from the Nationwide Readmissions Database. *J Am Coll Cardiol* Mar 2018, 71 (11 Supplement) A1100; DOI: 10.1016/S0735-1097(18)31641-3.
100. Bavishi C, Trivedi V, Chatterjee S, Abbott JD, **Aronow HD**, Stone G, Bangalore S. Bivalirudin Versus Heparin in Patient With Chronic Kidney Disease: Insights from Meta-Analysis of Randomized Trials. *J Am Coll Cardiol* Mar 2018, 71 (11 Supplement) A1124; DOI: 10.1016/S0735-1097(18)31665-6.
101. Patel YR, Moreno P, Bavishi C, Kolte D, Abbott J, **Aronow HD**. Transradial access is associated with lower risk of dialysis and acute renal failure than transfemoral access in patients undergoing cardiac catheterization or percutaneous coronary intervention. *J Am Coll Cardiol* Mar 2018, 71 (11 Supplement) A1266; DOI: 10.1016/S0735-1097(18)31807-2.
102. Kundu A, Sardar P, Chatterjee S, Bavishi C, Kakouros N, **Aronow H**, Rade J. Long Term Cardiovascular Outcomes with Drug-Eluting Stents vs. Bare-Metal Stents in Saphenous Vein Graft Interventions: Insights from an Updated Meta-Analysis of Randomized Controlled Trials. *J Am Coll Cardiol* Sep 2018, 72 (13 Supplement) B209-B210; DOI: 10.1016/j.jacc.2018.08.1701

103. Louis D, Lima F, Kolte D, Kennedy K, Abbott JD, **Aronow H**. Thirty-Day Readmissions After Medical vs. Endovascular Therapy for Atherosclerotic Renal Artery Stenosis: Insights from the National Readmissions Database. *J Am Coll Cardiol Sep* 2018, 72 (13 Supplement) B57-B58; DOI: 10.1016/j.jacc.2018.08.1239.
104. Kolte D, Kennedy K, Shishehbor M, Mustapha J, Soukas P, Hyder O, Mamdani S, **Aronow H**. Endovascular Versus Surgical Revascularization for Acute Limb Ischemia: A Propensity Matched Analysis of the National Inpatient Sample. *Catheter Cardiovasc Interv* 2018;91:S88.
105. Kolte D, Beale C, **Aronow HD**, Kennedy KF, Apostolidou E, Sellke FW, Sharaf BL, Gordon PC, Abbott JA, Ehsan A. Trends and Outcomes of Red Blood Cell Transfusion in Patients Undergoing Transcatheter Aortic Valve Replacement in the United States. *Circulation* 2018;138:A11102
106. Kumar A, Smolderen K, Gosch K, Jones P, Stone N, **Aronow H**, Beltrame J, Safley DM. Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy is Not Associated With Patient-Reported Peripheral Artery Disease Specific Health Status: Data From the PORTRAIT Study. *Circulation* 2018;138:A11998.
107. Salisbury AC, Safley DM, **Aronow HD**, Schuyler Jones W, Kennedy KF, Feldman DN, Secemsky E, Tsai TT, Attaran RR, Spertus JA. Development and Validation of a Model to Predict Post-Procedure Bleeding After Peripheral Vascular Intervention: A Report From the National Cardiovascular Data Registry PVI Registry. *Circulation* 2018;138:A12038.
108. Flood SP, Kennedy KF, Louis DW, **Aronow HD**. Validation of CathPCI Bleeding Model in Transradial vs. Transfemoral PCI Patients. *Circulation* 2018;138:A16927.
109. Rymer J, Kennedy K, Lowenstern A, Secemsky E, **Aronow H**, Gray B, Prasad A, Armstrong E, Rosenfield K, Shishehbor M, Jones S, Patel M. In-hospital outcomes and discharge medication use among patients presenting with critical limb ischemia versus claudication: Insights from the NCDR PVI Registry. *J Am Coll Cardiol March* 12, 2019, 73 (9 Supplement 1) 2036; DOI:10.1016/S0735-1097(19)32642-7
110. Jelani Q, Shah S, Yuanyuan T, Spertus JA, Smolderen K, **Aronow H**, Paredes M, Attaran R, Regan C, Mena-Hurtado C. Patterns and predictors of referral for invasive management of peripheral arterial disease in the United States: Insights from the PORTRAIT Registry. *J Am Coll Cardiol March* 12, 2019, 73 (9 Supplement 1) 2044; DOI:10.1016/S0735-1097(19)32650-6
111. Smolderen K, Safley D, Jones P, Patel M, Jones S, Shishehbor M, **Aronow H**, Labrosciano C, Fuss C, Scott K, Stone N, Spertus JA. One-year major adverse limb events and planned revascularization following invasive versus optimal medical therapy for new or worsening claudication symptoms: Insights from the PORTRAIT Registry. *J Am Coll Cardiol March* 12, 2019, 73 (9 Supplement 1) 2115; DOI:10.1016/S0735-1097(19)32721-4

112. Lam M, Kolte D, Kennedy K, Naidu S, Feldman D, Chu A, **Aronow H**. Incidence, timing and predictors of permanent pacemaker placement following alcohol septal ablation for hypertrophic cardiomyopathy. *J Am Coll Cardiol* March 12, 2019, 73 (9 Supplement 1) 1175; DOI:10.1016/S0735-1097(19)31782-6
113. Apostolidou E, Kolte D, Kennedy KF, Beale CE, Abbott DJ, Ehsan A, Gurm H, Carson J, Mamdani S, **Aronow HD**. Hospital transfusion culture independently predicts likelihood of transfusion following inpatient cardiovascular procedures. *J Am Coll Cardiol* March 12, 2019, 73 (9 Supplement 1) 1385; DOI:10.1016/S0735-1097(19)31992-8
114. Abdulsalam N, Elizabeth R Lyden ER, Abbott JD, **Aronow, HD**, Tak HJ, Velagapudi P, Pavlides G, O'Leary EL, Chatzizisis Y, Barton D, Goldsweig AM. The Changing Therapeutic Landscape for Severe Aortic Stenosis. SCAI 2019 Scientific Sessions. Las Vegas, NV; May 2017.
115. Klinkhammer B, Lyden E, Abbott JD, **Aronow H**, Porter T, and Goldsweig A. Dose-dependent effects of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers on clinical and echocardiographic outcomes after transcatheter aortic valve replacement. *J Am Coll Cardiol* 2019;74(13) Supplement. DOI: 10.1016/j.jacc.2019.08.187
116. Apostolidou E, Sellke FW, **Aronow HD**, Kolte D, Kennedy KF, Sodha NR, Fingleton JG, Ehsan A. Association between blood product transfusion and in-hospital clinical outcomes in patients undergoing type A aortic dissection repair in the United States. *Circulation* 2019;140:A14127.

## INVITED PRESENTATIONS

### Extramural – International

1. “Evaluation of the Atherosclerotic Plaque: Is Regression Possible?” National Institute of Cardiology, 60<sup>th</sup> Anniversary Cardiology Symposium. Mexico City, Mexico (April 21, 2004).
2. Atherosclerosis symposium. “Reducing Global Cardiovascular Risk with Early and Aggressive Statin Therapy.” Guadalajara, Mexico (April 22, 2004).
3. Atherosclerosis symposium. “Reducing Global Cardiovascular Risk with Early and Aggressive Statin Therapy.” Monterrey, Mexico (April 23, 2004).
4. “Carotid Stent: Predictors of success – patient, imaging studies, clinical presentation, lesion characteristics and other important factors.” India Live 2014. New Delhi, India (March 1, 2014).
5. “Carotid Stent: Predictors of success – patient, imaging studies, clinical presentation, lesion characteristics and other important factors.” India Live 2014. New Delhi, India (March 1, 2014).

6. “Renal Artery Stent: Techniques, tips and tricks.” India Live 2014. New Delhi, India (March 1, 2014).
7. “SFA/Pop: Chronic Total Occlusions: Techniques and assistant technologies.” India Live 2014. New Delhi, India (March 2, 2014).
8. “PAD: The Year In Review.” Canadian Cardiovascular Congress 2014. Vancouver, BC. (October 25, 2014).
9. “Catheter Directed Thrombectomy for Acute Pulmonary Embolism: Meds, Maceration or Mechanical Thrombectomy?” International Conference for Innovations in Cardiovascular Systems (ICI) 2018. Tel Aviv, Israel (December 3, 2018).
10. “Is ‘Leave Nothing Behind’ the Right Approach to the SFA?” 15th Biennial International Andreas Gruentzig Society Meeting. Puerto Natales, Chile (February 4, 2019).
11. “How Do We Harness the Power of Social Media?” 15th Biennial International Andreas Gruentzig Society Meeting. Puerto Natales, Chile (February 7, 2019).

#### Extramural - National

1. “ACS & PCI: Is there a role for statins?” University of Florida – Jacksonville Cardiology Grand Rounds. Jacksonville, FL (October 15, 2002).
2. “Cholesterol reduction, inflammation, and modification of cardiovascular risk.” Cardiovascular Keynote Address: South Bend Memorial Hospital Symposium. South Bend, IN (March 22, 2003).
3. “Brachial artery reactivity and intimal medial thickness.” Cleveland Clinic Foundation, *1<sup>st</sup> Annual Cardiovascular Imaging Summit*. Cleveland, OH (September 11, 2003).
4. “Carotid Stenting: Are We There Yet?” Interventional Cardiology Grand Rounds. University of Florida. Jacksonville, FL (December 9, 2003).
5. “Carotid Stenting: Trials & Tribulations.” University of Michigan Division of Cardiovascular Medicine Grand Rounds. Ann Arbor, MI (November 12, 2004).
6. Cleveland Clinic Carotid Summit. Carotid stent simulation proctor. Orlando, FL (March 4, 2005).
7. “Percutaneous Carotid Intervention Trials: A Review of the Evidence Base.” Cardiovascular Research Technologies 2005 Carotid Stenting Course. Washington, D.C. (March 28, 2005).
8. “Early Recognition and Management of PAD to Prevent Functional Impairment, Stroke and MI.” Grand Rounds, Good Samaritan Medical Center. Brockton, MA (April 29, 2005).
9. “Early Recognition and Management of PAD to Prevent Functional Impairment, Stroke and MI.” Grand Rounds, Oak Forest Hospital of Cook County. Oak Forest, IL (June 15, 2005).

10. 12<sup>th</sup> Annual New Devices Seminar. Carotid stent simulation proctor. Orlando, FL (June 30, 2005).
11. “Avoidance and Management of Complications During Carotid Stenting.” Cardiovascular Research Technologies 2006. Arlington, VA (April 6, 2006).
12. “High dose statin therapy for secondary prevention: Balancing the risks and benefits.” Graduate Hospital medical grand rounds. Philadelphia, PA (April 24, 2006).
13. “PAD and CAD: Similarities, differences, and evidence-based strategies to prevent vascular events. Southwest General Hospital medical grand rounds. Middleburg Heights, OH (July 7, 2006).
14. “PAD: Managing the Cross Risk Vascular Patient.” Long Beach Medical Center Medical Grand Rounds. Long Beach, NY (October 13, 2006).
15. “PAD:Applying the New ACC/AHA Guidelines.” Graduate Hospital Cardiology Grand Rounds. Philadelphia, PA (December 4, 2006).
16. “Carotid Stenting – Basics.” 2006 Transcatheter Cardiovascular Therapeutics Annual Scientific Satellite Symposium. Washington, D.C. (October 23, 2006).
17. “Carotid Stenting – Advanced.” 2006 Transcatheter Cardiovascular Therapeutics Annual Scientific Satellite Symposium. Washington, D.C. (October 23, 2006).
18. “Meet the Experts - Endovascular, Carotid Case Reviews.” American College of Cardiology/i2 2011 Annual Scientific Sessions. New Orleans, LA (April 3, 2011).
19. “Management of the Patient with Concomitant Carotid and Coronary Artery Disease.” Extracranial Carotid Artery Disease: The Challenge – Which Therapy for Which Patient? American College of Cardiology/i2 2011 Annual Scientific Sessions. New Orleans, LA (April 5, 2011).
20. “Case presentation: Supported PCI with the IABP” Hemodynamic support in high-risk PCI or Shock. Society of Cardiovascular Angiography & Intervention 2011 Scientific Sessions. Baltimore, MD (May 6, 2011).
21. “Statins and Atherosclerotic Vascular Disease: Which Vascular Beds Benefit? “ Transcatheter Cardiovascular Therapeutics 2011 Annual Scientific Symposium. San Francisco, CA (November 7, 2011).
22. “Treatment of Carotid Artery Disease: PTA is the way!” 20<sup>th</sup> Annual Cardiovascular Nurse and Technologist Symposium II – The Great Debate. Transcatheter Cardiovascular Therapeutics 2011 Annual Scientific Symposium. San Francisco, CA (November 8, 2011).
23. “Drug Eluting Balloons: Where do we Stand in 2012?” American College of Cardiology/i2 2012 Annual Scientific Sessions. Chicago, IL (March 25, 2012).

24. Debate - Pro: "Carotid Stenting Should be Considered an Alternative to CEA for Symptomatic Carotid Disease in Average Surgical Risk Patients." American College of Cardiology/i2 2012 Annual Scientific Sessions. Chicago, IL (March 26, 2012).
25. "Assessment of vascular diseases in patients with CKD." 2012 Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions. Las Vegas, NV (May 9, 2012).
26. "From Sapphire to CREST what's new with carotid revascularization?" 2012 Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions. Las Vegas, NV (May 9, 2012).
27. "CAS Following CREST: Now That the Noise Has Died, What is the Role of the Therapy?" Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. Miami, FL (October 22, 2012).
28. Session Moderator. Lower Extremity PAD: Claudicants. American College of Cardiology/TCT@ACC 2013 Annual Scientific Sessions. San Francisco, CA (March 10, 2013).
29. Debate – Pro: "An Endovascular First Approach is Preferred Therapy for TASC C/D." American College of Cardiology/TCT@ACC 2013 Annual Scientific Sessions. San Francisco, CA (March 10, 2013).
30. Session Moderator. Fellows Bootcamp: Peripheral Vascular Disease for Fellows. American College of Cardiology/TCT@ACC 2013 Annual Scientific Sessions. San Francisco, CA (March 11, 2013).
31. Session Moderator. Critical Peripheral Ischemic Syndromes. Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions. Orlando, FL (May 8, 2013).
32. "Carotid artery stenosis - CAS is the revascularization modality of choice for symptomatic disease." Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions. Orlando, FL (May 8, 2013).
33. Session Moderator. "An Insider's Guide to Social Media Success in Cardiovascular Medicine." Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions. Orlando, FL (May 10, 2013).
34. "Appropriate Use of Social Media in Cardiovascular Medicine." Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions. Orlando, FL (May 10, 2013).
35. "The Year in Review: PAD." Society for Vascular Medicine Annual Meeting. Cleveland, OH (June 13, 2013).
36. "Are there subpopulations in which renal nerve ablation might not be appropriate?" American Society of Hypertension Workshop on the Detection, Evaluation, and Management of Severe and Resistant Hypertension. Bethesda, MD (October 10, 2013).

37. "Statistics and Clinical Study Design: Teaching Through Example." Transcatheter Cardiovascular Therapeutics iASSESS Interventional Cardiology Board Review Course. San Francisco, CA (October 27, 2013).
38. "Should the CLEVER Trial Results Materially Affect Decision-Making in Iliac Disease?" Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Francisco, CA (October 27, 2013).
39. Discussant, Aortoiliac and Femoropopliteal Intervention. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Francisco, CA (October 27, 2013).
40. Live Case Discussant. How to Treat Theater: Endovascular Disease. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Francisco, CA (October 30, 2013).
41. Co-Chair. PCI - Trials. American College of Cardiology/TCT@ACC 2014 Annual Scientific Sessions. Washington, DC (March 29, 2014).
42. Moderator. Controversies in Vascular Medicine. American College of Cardiology/TCT@ACC 2014 Annual Scientific Sessions. Washington, DC (March 31, 2014).
43. "Debate: Renal Artery Stenting - Dead in the CORAL Reef (PRO)." American College of Cardiology/TCT@ACC 2014 Annual Scientific Sessions. Washington, DC (March 31, 2014).
44. "Controversies in Peripheral Vascular Therapy - Best Therapy for Claudication Is Endovascular." American College of Cardiology/TCT@ACC 2014 Annual Scientific Sessions. Washington, DC (March 31, 2014).
45. "When To Consider Renal Denervation Therapy." American Society of Hypertension Annual Scientific Meeting 2014. New York, NY (May 19, 2014).
46. Moderator. Appropriate Use Criteria. 2014 Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions. Las Vegas, NV (May 28, 2014).
47. "Intended and unintended Uses for AUC – Prognosis/reimbursement." 2014 Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions. Las Vegas, NV (May 28, 2014).
48. "The Science and Physiologic Basis for Renal Denervation Therapies." 2014 Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions. Las Vegas, NV (May 31, 2014).
49. "Clinical Conundrums: My patient has a carotid dissection, now what?" 2014 Society for Vascular Medicine Annual Meeting. San Diego, CA (June 12, 2014).



50. “Statistics and Clinical Study Design: Teaching Through Example.” Transcatheter Cardiovascular Therapeutics iASSESS Interventional Cardiology Board Review Course. Washington, DC (September 13, 2014).
51. Moderator. “Taking Your Career To The Next Level: Achieving Local, Regional and National Success.” Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. Washington, DC (September 14, 2014).
52. Digital Moderator. “Controversies in Transradial PCI.” Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. Washington, DC (September 16, 2014).
53. Panelist. Case Theater: PAD/Vascular Surgery-Retrograde Pedal Access Case. American Heart Association Scientific Sessions. Chicago, IL (November 17, 2014).
54. “Carotid Artery Stenting 2005-2015: From Controversy to Consensus.” Lifespan Cardiovascular Institute Lecture. Providence, RI (February 25, 2015).
55. “Debate: Creation of Appropriate Use Criteria for Endovascular Therapies: AUC for PVD Create Unintended Consequences and Will Hamper Our Ability to Do What We Think Is Best.” American College of Cardiology/TCT@ACC 2015 Annual Scientific Sessions. San Diego, CA (March 14, 2015).
56. “Workup of the Weird—Vascular Medicine for the Cardiologist: Vascular Causes of Abdominal Pain.” American College of Cardiology/TCT@ACC 2015 Annual Scientific Sessions. San Diego, CA (March 14, 2015).
57. Moderator. “AUC: A Case-Based Approach.” 2015 Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions. San Diego, CA (May 7, 2015).
58. “Downstream Consequences of AUC Reporting.” 2015 Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions. San Diego, CA (May 7, 2015).
59. Panelist. Renal Denervation: Hopes and Dreams. 2015 Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions. San Diego, CA (May 9, 2015).
60. Panelist. C3 Summit for Fellows In Training – Peripheral Interventions. 2015 Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions. San Diego, CA (May 9, 2015).
61. “Critical Limb Ischemia for the Non-Interventionalist: Future Trials.” 2015 Society for Vascular Medicine Annual Meeting. Baltimore, MD (June 11, 2015).
62. “Upper Extremity Arterial Disease: Subclavian stenosis and subclavian and coronary subclavian steal syndromes.” 2015 Society for Vascular Medicine Annual Meeting. Baltimore, MD (June 11, 2015).
63. “Intermittent Claudication Patients.” Representing the American College of Cardiology at the Centers for Medicare and Medicaid Services (CMS) Medicare Evidence Development

and Coverage Advisory Committee (MEDCAC) Lower Extremity Peripheral Artery Disease Meeting. (July 22, 2015).

64. “Surgical Considerations in Aorto-Iliac Disease: Is the CFA a ‘No Stent’ Zone?” Society for Cardiovascular Angiography and Interventions Complex Peripheral Vascular Interventions (CPVI) 2015. Washington, DC (September 26, 2015).
65. “Management of SFA/Popliteal Complications.” Society for Cardiovascular Angiography and Interventions Complex Peripheral Vascular Interventions (CPVI) 2015. Washington, DC (September 26, 2015).
66. “Management of SFA/Popliteal Complications.” Society for Cardiovascular Angiography and Interventions Complex Peripheral Vascular Interventions (CPVI) 2015. Washington, DC (September 26, 2015).
67. Discussant. Lower Extremity Intervention: SFA and Popliteal. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Francisco, CA (October 11, 2015).
68. “Two US PAD Trials That May Well Change Your Practice: Updates on the ENDOMAX and LIBERTY-360 Studies.” Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Francisco, CA (October 11, 2015).
69. “When and How to Treat A Claudicant With an Occluded SFA” Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Francisco, CA (October 14, 2015).
70. Discussant. Carotid Disease and Treatment. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Francisco, CA (October 14, 2015).
71. “Should Carotid Stenting Volume Requirements Be Markedly Decreased or Eliminated? Nonsense, Patient Safety Above All Else!” Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Francisco, CA (October 14, 2015).
72. “Tracking Patient Outcomes after Endovascular Intervention in the Real World.” American Heart Association Annual Scientific Sessions 2015. Orlando, FL (November 8, 2015).
73. “A Difficult Conversation: How to Talk to the Family When a Patient Dies.” Society for Cardiovascular Angiography and Interventions Fall Fellows Course. Las Vegas, NV (12/7/15)
74. Panelist. High Risk Interventions and Support Technology. Society for Cardiovascular Angiography and Interventions Fall Fellows Course. Las Vegas, NV (12/7/15)
75. “Renal Intervention.” Society for Cardiovascular Angiography and Interventions Fall Fellows Course. Las Vegas, NV (12/8/15)

76. "Access Closure – Manual vs. Device with Case Examples." Society for Cardiovascular Angiography and Interventions Fall Fellows Course. Las Vegas, NV (12/8/15)
77. Panelist. Peripherals. Society for Cardiovascular Angiography and Interventions Fall Fellows Course. Las Vegas, NV (12/8/15)
78. Co-chair. Debates in Endovascular Therapy: Intervention for Cerebrovascular Disease. American College of Cardiology American College of Cardiology/TCT@ACC 2016 Annual Scientific Sessions. Chicago, IL (April 3, 2016).
79. "Delivering High Value Vascular Care in 2016 – When PVI Meets the Media and MEDCAC." American College of Cardiology American College of Cardiology/TCT@ACC 2016 Annual Scientific Sessions. Chicago, IL (April 3, 2016).
80. Co-chair. Gritty Lesions, Great Insights: Cases, Consensus, and Occasional Confusion in Femoropopliteal PAD Intervention. American College of Cardiology American College of Cardiology/TCT@ACC 2016 Annual Scientific Sessions. Chicago, IL (April 4, 2016).
81. "How Will PVI AUC Influence Practice in the Treatment of Femoropopliteal PAD?" American College of Cardiology American College of Cardiology/TCT@ACC 2016 Annual Scientific Sessions. Chicago, IL (April 4, 2016).
82. Case Presenter. Learning From PCI Complications - Bleeding Complication. American College of Cardiology American College of Cardiology/TCT@ACC 2016 Annual Scientific Sessions. Chicago, IL (April 4, 2016).
83. "Renal Artery Revascularization: Are There Any Remaining Indications?" American College of Cardiology – Puerto Rico Chapter Annual Meeting. San Juan, PR (April 29, 2016).
84. "Approach to the Patient With Peripheral Artery Disease." American College of Cardiology – Puerto Rico Chapter Annual Meeting. San Juan, PR (April 30, 2016).
85. "Carotid Stenting in 2016: Challenges and Opportunities." American College of Cardiology – Puerto Rico Chapter Annual Meeting. San Juan, PR (April 30, 2016).
86. "The Media and Endovascular Intervention — Appropriately Critical or Sensationalistic" 2016 Society for Vascular Medicine Annual Meeting. Long Beach, CA (June 16, 2016).
87. "Board Review: Evaluation and Treatment of Renal Artery Disease." 2016 Society for Vascular Medicine Annual Meeting. Long Beach, CA (June 16, 2016).
88. Case presenter. Interventional Show and Tell Madness: Our Most Challenging Interventions of the Year. 2016 Society for Vascular Medicine Annual Meeting. Long Beach, CA (June 17, 2016).
89. Case presenter. Complications of Radial Interventions, Including Thrombosis, Spasm, Kinks, Dissections, Ischemia and Ruptures - Preventive and Procedural Expertise to Save the

- Access and Knowing When Radial Won't Work. Vascular Interventional Advances (VIVA). Las Vegas, NV (September 21, 2016).
90. Live Case Panelist: Tokeidai Memorial Hospital. Vascular Interventional Advances (VIVA). Las Vegas, NV (September 21, 2016).
  91. Live Case Panelist: AZ Sint Blasius Hospital. Vascular Interventional Advances (VIVA). Las Vegas, NV (September 21, 2016).
  92. Discussant. Renal and Mesenteric Ischemia. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. Washington, DC (October 30, 2016).
  93. "The Optimal Management of Chronic Mesenteric Ischemia Is Catheter-based Intervention!" Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. Washington, DC (October 30, 2016).
  94. "Should Complete Revascularization in STEMI and Multivessel Disease Be Performed During the Index Procedure? No, In the Middle of the Night and With Complex Anatomy – Are You Kidding?!" Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. Washington, DC (November 1, 2016).
  95. "Top Five Innovations That Will Change the Interventional Cardiology Field-The Next Big Hit in Peripheral Interventions." American Heart Association Scientific Sessions. New Orleans, LA (November 14, 2016).
  96. Co –Chair. Debates on Current Hot Topics in Coronary Intervention. American College of Cardiology 2017 Annual Scientific Sessions. Washington, DC (March 17, 2017).
  97. Chair. Core Curriculum: Head to Toe Catheter Based Interventions. American College of Cardiology 2017 Annual Scientific Sessions. Washington, DC (March 18, 2017).
  98. Speaker. Felows Bootcamp: Peripheral Vascular Disease and Structural Heart Disease Management – Renal, Carotid, Subclavian. American College of Cardiology 2017 Annual Scientific Sessions. Washington, DC (March 19, 2017).
  99. Co-Chair. Born to Run: Geographic Variation in PAD Diagnosis, Treatment and Outcomes. American College of Cardiology 2017 Annual Scientific Sessions. Washington, DC (March 19, 2017).
  100. Speaker. Access Selection: Antegrade vs. Retrograde "Up and Over." Is Radial an Option? Transpedal/Tibial Access. SCAI Complex Peripheral Vascular Intervention. Society for Cardiovascular Angiography and Interventions 2017 Annual Scientific Sessions. New Orleans, LA (May 10, 2017).
  101. Speaker. Complications Potpourri. SCAI Complex Peripheral Vascular Intervention. Society for Cardiovascular Angiography and Interventions 2017 Annual Scientific Sessions. New Orleans, LA (May 10, 2017).

102. Panelist. VIVA @ SCAI: Challenges and Controversies in Peripheral Vascular Intervention. Society for Cardiovascular Angiography and Interventions 2017 Annual Scientific Sessions. New Orleans, LA (May 11, 2017).
103. Panelist. SFA Endo First. Society for Cardiovascular Angiography and Interventions 2017 Annual Scientific Sessions. New Orleans, LA (May 11, 2017).
104. Speaker. Case Examples: DCB vs. Stenting – When Do I Just Leave It? Society for Cardiovascular Angiography and Interventions 2017 Annual Scientific Sessions. New Orleans, LA (May 11, 2017).
105. Moderator. C3 Summit for Interventional Fellows-In-Training. Society for Cardiovascular Angiography and Interventions 2017 Annual Scientific Sessions. New Orleans, LA (May 12, 2017).
106. Speaker. Great Debates in Vascular Medicine – Some CLI Patients Should be Offered Palliative Care as Intervention Can Be More Harmful Than Beneficial. 2017 Society for Vascular Medicine Annual Meeting. New Orleans, LA (June 16, 2017).
107. Speaker. Mesenteric Arterial Syndromes. Society for Vascular Medicine Board Review Course. New Orleans, LA (June 17, 2017).
108. Moderator. Peripheral Artery Disease. Society for Vascular Medicine Board Review Course. New Orleans, LA (June 17, 2017).
109. Speaker. Endovascular Therapy for Claudication. Society for Vascular Medicine Board Review Course. New Orleans, LA (June 17, 2017).
110. Speaker. Catheter-Based Intervention for PE. Society for Vascular Medicine Board Review Course. New Orleans, LA (June 18, 2017).
111. Discussant. SFA and Tibial Artery Lesion Preparation. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. Denver, CO (October 30, 2017).
112. Discussant. Bootcamp II: Cath Lab Economics and Payments: Mastering MACRA (Medicare Access and CHIP Reauthorization Act). Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. Denver, CO (October 31, 2017).
113. Speaker. “How to Align Incentives in the Cath Lab.” Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. Denver, CO (October 31, 2017).
114. Moderator. Catheter-Directed Therapy for Acute Pulmonary Embolism: Ready for Primetime or Work-in-Progress? American Heart Association Scientific Sessions. Anaheim, CA (November 12, 2017).

115. Speaker. “Expanding Our Options for Pharmacomechanical and Mechanical Therapy in Acute PE Patients: Advances in Catheter-Based Embolectomy.” American Heart Association Scientific Sessions. Anaheim, CA (November 12, 2017).
116. Speaker. “What is Iliac Vein Compression Syndrome? When to Treat and When to Hold Off?” Society for Vascular Medicine Fall Fellows Course. Atlanta, GA (December 3, 2017).
117. Speaker. “When to Intervene in Renal Artery Stenosis.” Society for Vascular Medicine Fall Fellows Course. Atlanta, GA (December 3, 2017).
118. Moderator. ELM Panel: Early Career Advice, Transitions in Practice. Society for Cardiovascular Angiography and Intervention Fall Fellows Course. Las Vegas, NV (December 11, 2017)
119. Speaker. “Carotid Stenosis.” Society for Cardiovascular Angiography and Intervention Fall Fellows Course. Las Vegas, NV (December 11, 2017)
120. Co-Chair. Cardiovascular Medicine in 140 Characters: Making the Most of #SoMe. American College of Cardiology Annual Scientific Session 2018, Orlando, FL (March 11, 2018).
121. Speaker. “My Twitter Was Hacked: Stop Making Excuses and Avoid Social Media Pitfalls.” American College of Cardiology Annual Scientific Session 2018, Orlando, FL (March 11, 2018).
122. Co-Chair. Highlighted Original Research: Vascular Medicine and the Year in Review. American College of Cardiology Annual Scientific Session 2018, Orlando, FL (March 11, 2018).
123. Speaker. “Carotid and Subclavian Artery Disease.” Fellows Bootcamp: Peripheral Vascular Disease. American College of Cardiology Annual Scientific Session 2018, Orlando, FL (March 12, 2018).
124. Speaker. “Social Media in Vascular Medicine.” ACC.18 PVD Section Highlights Session. American College of Cardiology Annual Scientific Session 2018, Orlando, FL (March 12, 2018).
125. Speaker. “Complications Potpourri.” Complex Peripheral Vascular Intervention. Society for Cardiovascular Angiography and Interventions 2018 Annual Scientific Sessions. San Diego, CA (April 25, 2018).
126. Panelist. New Frontiers in Acute and Chronic Thromboembolic Pulmonary Disease. Society for Cardiovascular Angiography and Interventions 2018 Annual Scientific Sessions. San Diego, CA (April 26, 2018).
127. Speaker. “Invasive Management of Intermediate and High-Risk PE: Tools of the Trade.” Society for Cardiovascular Angiography and Interventions 2018 Annual Scientific Sessions. San Diego, CA (April 26, 2018).

128. Moderator. SCAI/ACC Joint Session II: Registries, Reporting and Quality Metrics. Society for Cardiovascular Angiography and Interventions 2018 Annual Scientific Sessions. San Diego, CA (April 26, 2018).
129. Speaker. “Drug-Coated Balloons: Can We Leave Nothing Behind? Is it a Class Effect?” Society for Cardiovascular Angiography and Interventions 2018 Annual Scientific Sessions. San Diego, CA (April 26, 2018).
130. Moderator. Carotid Artery Disease: Carotid Endarterectomy, Stenting or Back to Medical Therapy? Society for Cardiovascular Angiography and Interventions 2018 Annual Scientific Sessions. San Diego, CA (April 27, 2018).
131. Speaker. “Transcarotid Artery Revascularization: Is There a Role for the Interventional Cardiologist?” Society for Cardiovascular Angiography and Interventions 2018 Annual Scientific Sessions. San Diego, CA (April 27, 2018).
132. Speaker. “The Year In Vascular Medicine: Arterial Interventions.” 2018 Society for Vascular Medicine Annual Meeting. Chicago, IL (June 14, 2018).
133. Moderator. The Future of Vascular Imaging. 2018 Society for Vascular Medicine Annual Meeting. Chicago, IL (June 14, 2018).
134. Moderator. Medical Management of PAD. 2018 Society for Vascular Medicine Annual Meeting. Chicago, IL (June 14, 2018).
135. Speaker. “Carotid Artery Stenting: Synthesizing the Current Randomized Trial Evidence.” Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Diego, CA (September 21, 2018).
136. Speaker. TCT Endovascular: Fellows Course – “Clinical Pearls: Carotid Disease Diagnosis and Treatment” (September 22, 2018).
137. Discussant. TCT Endovascular: Fellows Course. Case Reviews: So You Think You Can Be a Vascular Specialist? Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Diego, CA (September 22, 2018).
138. Moderator. TCT Endovascular: Expert Case Reviews: SFA, Popliteal, and Below the Knee Intervention. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Diego, CA (September 22, 2018).
139. Moderator. Renal Denervation Poster Session. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Diego, CA (September 23, 2018).
140. Discussant. Live Cases: Endo. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Diego, CA (September 23, 2018).

141. Discussant. Live Case Theater: Endovascular. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Diego, CA (September 24, 2018).
142. Discussant. Complications of Endovascular Interventions. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Diego, CA (September 24, 2018).
143. Speaker. TCT Endovascular: Expert Case Reviews - Complications of Endovascular Interventions: "Carotid Stent Thrombosis." Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Diego, CA (September 24, 2018).
144. Discussant. Management of Hypertension: Treatment Options. Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Diego, CA (September 24, 2018).
145. Speaker. "The ACC Registry: How it's Working and Where it's Going." American Heart Association Scientific Sessions. Chicago, IL (November 10, 2018).
146. Moderator. Gearing Up: Tools, Strategies, and Drugs for Optimal Intervention. Society for Cardiovascular Angiography and Intervention Fall Fellows Course. Las Vegas, NV (December 8, 2018).
147. Moderator. Case Reviews With the Experts: What Would You Do? Society for Cardiovascular Angiography and Intervention Fall Fellows Course. Las Vegas, NV (December 8, 2018).
148. Speaker. "Cath Lab Disasters: What to Do When Cases Go Bad." Society for Cardiovascular Angiography and Intervention Fall Fellows Course. Las Vegas, NV (December 8, 2018).
149. Moderator. Best of Cath Lab Boot Camp. Society for Cardiovascular Angiography and Intervention Fall Fellows Course. Las Vegas, NV (December 9, 2018).
150. Moderator. Early Career Advice and Transitions in Practice. Society for Cardiovascular Angiography and Intervention Fall Fellows Course. Las Vegas, NV (December 10, 2018).
151. Moderator. Complex Peripheral Vascular Intervention. Society for Cardiovascular Angiography and Intervention Fall Fellows Course. Las Vegas, NV (December 10, 2018).
152. Speaker. "Carotid Stenosis." Society for Cardiovascular Angiography and Intervention Fall Fellows Course. Las Vegas, NV (December 11, 2018).
153. Problem Presenter. "Interventional and Surgical Therapies for Massive PE: What's PERTinent?" International Andreas Gruentzig Society meeting. Puerto Morales, Chile (February 5, 2019)
154. Problem Presenter. "Renal Denervation for Moderate and Severe Hypertension: Waiting for Godot?" International Andreas Gruentzig Society meeting. Puerto Morales, Chile (February 7, 2019)



155. Speaker. "Rox Coupler: Can We Shunt the BP Away?" Cardiovascular Research Technologies. Washington, DC (March 5, 2019)
156. Speaker "Fem-pop Interventions: Can we Leave Nothing Behind?" Cardiovascular Research Technologies. Washington, DC (March 5, 2019)
157. Panelist. "Innovative Technology Update: Have we Optimized the Technology?" Cardiovascular Research Technologies. Washington, DC (March 5, 2019)
158. Panelist. "Femoropopliteal Arterial Disease" Cardiovascular Research Technologies. Washington, DC (March 5, 2019)
159. Speaker. "Renal Artery Stenting: Are There Any Remaining Indications?" Cardiovascular Research Technologies. Washington, DC (March 5, 2019)
160. Speaker. "Device Therapy for Hypertension: Are Pills Passé?" University of Toledo College of Medicine and Life Sciences Cardiovascular Division Grand Rounds. Toledo, OH (April 19, 2019).
161. Panelist. "SCAI Complex Peripheral Vascular (SCAI-CPVI) Summit: Interactive Case Discussions." Society for Cardiovascular Angiography and Interventions 2019 Annual Scientific Sessions. Las Vegas, NV (May 20, 2019).
162. Moderator. "SCAI Complex Peripheral Vascular (SCAI-CPVI) Summit: Aortic Bifurcation." Society for Cardiovascular Angiography and Interventions 2019 Annual Scientific Sessions. Las Vegas, NV (May 20, 2019).
163. Panelist. "Claudication: When Conservative Management Fails." Society for Cardiovascular Angiography and Interventions 2019 Annual Scientific Sessions. Las Vegas, NV (May 21, 2019).
164. Speaker. "Managing Diffuse SFA Disease and Chronic Total Occlusions." Society for Cardiovascular Angiography and Interventions 2019 Annual Scientific Sessions. Las Vegas, NV (May 21, 2019).
165. Panelist. "Case-Based Carotid and Subclavian Interventions." Society for Cardiovascular Angiography and Interventions 2019 Annual Scientific Sessions. Las Vegas, NV (May 21, 2019).
166. Moderator. "The Year In Vascular Medicine." 2019 Society for Vascular Medicine Annual Meeting. McLean, VA (May 30, 2019).
167. Speaker. "Popliteal Artery Thrombus." 2019 Society for Vascular Medicine Annual Meeting. McLean, VA (May 30, 2019).
168. Speaker. "Great Debates in Vascular Medicine - Con: All patients with stable PAD should be treated with rivaroxaban 2.5 mg BID and ASA (COMPASS). 2019 Society for Vascular Medicine Annual Meeting. McLean, VA (June 1, 2019).

169. Speaker. "Multispecialty and multi-society coalition for patient safety with paclitaxel technologies: Next steps". FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee. Gaithersburg, MD (June 19, 2019).
170. Discussant. "Acute Pulmonary Embolism." Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Francisco, CA (September 26, 2019).
171. Speaker. "Preventing PE in the Cardiac Patient: What Therapies and for Whom?" Transcatheter Cardiovascular Therapeutics Annual Scientific Symposium. San Francisco, CA (September 26, 2019).
172. Speaker. "Controversies in the Claudicant: From Walking Therapy to Intervention." Society for Cardiovascular Angiography and Interventions Fall Fellows Course. Las Vegas, NV (December 6, 2019).
173. Panelist. "Becoming an Endovascular Specialist." Society for Cardiovascular Angiography and Interventions Fall Fellows Course. Las Vegas, NV (December 6, 2019).
174. Moderator. "Gearing Up: Tools, Strategies, and Drugs for Optimal Intervention." Society for Cardiovascular Angiography and Interventions Fall Fellows Course. Las Vegas, NV (December 7, 2019).
175. Speaker. "Renal Artery Stenting and Denervation" Society for Cardiovascular Angiography and Interventions Fall Fellows Course. Las Vegas, NV (December 9, 2019).
176. Speaker. "Carotid Stenosis" Society for Cardiovascular Angiography and Interventions Fall Fellows Course. Las Vegas, NV (December 10, 2019).
177. Moderator. "Complex Peripheral Vascular Intervention." Society for Cardiovascular Angiography and Interventions Fall Fellows Course. Las Vegas, NV (December 10, 2019).

#### Extramural – Regional

1. "Statins: Should they be in the water? Current and future cardiovascular applications." Medical Grand Rounds, Firelands Hospital. Sandusky, OH (October 23, 2002).
2. "State of the statin address: Domestic and foreign issues." Ohio Osteopathic Association 5<sup>th</sup> District Meeting. Sandusky, OH (January 28, 2003).
3. "Cholesterol reduction, inflammation, and modification of cardiovascular risk". Hamot Medical Center Grand Rounds. Erie, PA (February 6, 2003).
4. "Statins for stable and unstable coronary syndromes." Medical Resident Noon Lecture Series. Meadville Medical Center. Meadville, OH (February 6, 2003).
5. "Technical Aspects of Carotid Stenting" Peripheral Vascular Disease Roundtable. Philadelphia, PA (March 2, 2004).

6. "Early and Aggressive Statin Therapy." Union County Medical Society. Milton, PA (April 20, 2004).
7. "Carotid stenting: Is It Ready For Prime Time?" Wilkes-Barre Veterans Administration Medical Center. Wilkes-Barre, PA (May 18, 2004).
8. "Secondary Prevention in the Era of Aggressive Statin Therapy: Key Issues." Grand Rounds. Chambersburg Hospital. Chambersburg, PA (July 23, 2004).
9. "A Practical and Aggressive Approach to Managing Lipids." Mercy Suburban Hospital Family Practice Update. Blue Bell, PA (August 19, 2004).
10. "Latest Advances In Treating Dyslipidemia" Montgomery Hospital Grand Rounds. Norristown, PA (October 13, 2004).
11. "Aggressive Statin Therapy In The Geriatric Population: To Be Written Off or Written For?" Delaware Academy of Family Medicine 19th Annual Geriatrics Symposium. Wilmington, DE (December 14, 2004).
12. "Balancing Statin Safety With Efficacy." Grand Rounds, Lankenau Hospital. Wynnewood, PA (May 20, 2005).
13. "Managing the High-Risk Vascular Patient." Passaic Regional Medical Center. Passaic, NJ (April 7, 2006).
14. "How to Get a Leg Up on PAD: Keys to early diagnosis and management." Lub, Dub & Splash 2006. Boyne Falls, MI (July 14, 2006).
15. "Is It Time To Up The 'Ante'? Optimal Antiplatelet Therapy For Primary and Secondary Prevention." Michigan State Medical Society Foundation Annual Scientific Meeting: Cardiology Update. Troy, MI (October 25, 2006).
16. "Choosing Your Specialty." University of Michigan Pre-Med Honors Society. Ann Arbor, MI (March 13, 2007).
17. "Carotid stenting: Is It Ready For Prime Time." Michigan Neurological Association Winter Meeting. Ann Arbor, MI (February 9, 2008).
18. "Aggressive Lipid Lowering Therapy" Spectrum Health – Blodgett Hospital Internal Medicine Grand Rounds. Grand Rapids, MI (April 17, 2008).
19. "A multidisciplinary approach to caring for patients with PAD" - PAD Symposium, American College of Cardiology - Michigan Chapter, 20<sup>th</sup> Annual Meeting. Traverse City, MI (September 26, 2008).
20. "Carotid Artery Stenosis: Where Are We Headed?" Michigan State Medical Society 143<sup>rd</sup> Annual Scientific Meeting. Troy, MI (October 23, 2008).

21. "Aggressive statin therapy." Garden City Hospital Cardiology Grand Rounds. Garden City, MI (May 27, 2009).
22. "Peripheral vascular intervention" Cardiology Update. Genesys Regional Medical Center. Grand Blanc, MI (October 14, 2009).
23. Moderator, PCI/PVI Session. 21<sup>st</sup> Annual American College of Cardiology, Michigan Chapter Conference. Grand Rapids, MI (October 16, 2009).
24. "Carotid Artery Intervention for Stroke Prevention" Michigan State Medical Society 144<sup>th</sup> Annual Scientific Meeting. Troy, MI (October 23, 2009).
25. "Preventing Transfusion: Why Do We Care." Blue Cross Blue Shield Percutaneous Coronary Intervention/Percutaneous Vascular Intervention statewide consortium meeting. Ann Arbor, MI (April 23, 2010).
26. "Challenging Cases: Peripheral Vascular Intervention." 22<sup>nd</sup> Annual American College of Cardiology, Michigan Chapter Conference. Traverse City, MI (October 9, 2010).
27. "Carotid Artery Disease: Where Are We Headed with Stenting and Surgery?" Michigan State Medical Society 145<sup>th</sup> Annual Scientific Meeting. Troy, MI (October 22, 2010).
28. "Vascular Access Site Bleeding." University of Michigan School of Engineering, Biomedical Engineering 599. Ann Arbor, MI (October 26, 2010).
29. Panelist. "A Case Based Approach to Controversies in Ischemic Heart Disease." Blue Cross Blue Shield of Michigan – Percutaneous Coronary Intervention/Michigan Society of Thoracic and Cardiovascular Surgeons Collaboratives Joint Meeting. Ann Arbor, MI (March 5, 2011).
30. "Endovascular Treatment of Abdominal Aortic Aneurysm (EVAR)" Michigan State Medical Society 146<sup>th</sup> Annual Scientific Meeting. Troy, MI (October 27, 2011).
31. "SYMPPLICITY HTN-3: Will catheter-based renal sympathetic denervation replace pharmacotherapy for treatment of HTN?" Borgess Medical Center Cardiovascular Grand Rounds. Kalamazoo, MI (November 30, 2012).
32. "Renal Denervation - Ablating HTN One Sympathetic Nerve at a Time." Michigan State Medical Society Spring Scientific Session. Troy, MI (May 17, 2013).
33. "Ten Best Interventional Papers From Last Year" 25<sup>th</sup> Annual American College of Cardiology, Michigan Chapter Conference. Detroit, MI (September 28, 2013).
34. "New and Emerging Technologies for the Treatment of Claudication and Critical Limb Ischemia." Ann Arbor area Podiatry meeting (May 8, 2014).

35. “Radial (not Femoral) Approach Should be the Default Approach for all Patients - Pro.” 26th Annual American College of Cardiology, Michigan Chapter Conference. Grand Rapids, MI (October 18, 2014).
36. “SOCRATES Same Day Discharge Study.” BMC2 PCI Registry Physicians Meeting. Grand Rapids, MI (October 18, 2014).
37. “Contemporary Management of Carotid Artery Disease.” 1<sup>st</sup> Annual Brown Advanced Cardiovascular Therapies Symposium. Providence, RI (October 15, 2016).
38. “Peripheral Artery Disease.” For the CV Team By the CV Team. American College of Cardiology Rhode Island Chapter. Providence, RI (May 11, 2018)
39. “Update on Cardiac Arrest: Have We Moved the Needle?” New England Council for Emergency Medical Services. Newport, RI (November 19, 2018).
40. “Cardiogenic Shock: A Case-Based Approach.” 12<sup>th</sup> Annual Rhode Island Emergency Medical Services Expo. Warwick, RI (April 23, 2019).
41. “Catheter-Directed Therapy for Pulmonary Embolism.” Advanced Cardiology for the Cardiovascular Team. Providence, RI (May 10, 2019).
42. “Radial First: Why Femoral Access Should Be ReLEGated to the Past!” 2nd Brown Cardiovascular Therapies Symposium. Providence, RI (November 9, 2019).
43. “Update in Management of Cardiogenic Shock” New England Council for Emergency Medical Services. Newport, RI (November 25, 2019).

#### Intramural

1. “Brachial artery reactivity testing: Fact, Fiction or Function.” Cleveland Clinic Foundation Department of Cardiovascular Medicine, Echocardiography Research Grand Rounds. Cleveland, OH (May 23, 2000).
2. “Statins: Should they be in the water? Current and future cardiovascular applications.” New Frontiers in Cardiovascular Medicine Lecture, Cleveland Clinic Foundation. Cleveland, OH (September 21, 2001).
3. “Risk stratification post acute coronary syndromes: When and what modality?” Cleveland Clinic Foundation, *An Intensive Review of Cardiology*. Cleveland, OH (October 11, 2001).
4. “Vascular endothelium and brachial reactivity: Fact, fiction or function.” Cleveland Clinic Cardiovascular Coordinating Center. Cleveland, OH (November 20, 2001).
5. “Statins: How to keep your Valentine happy (or at least event-free)!” Cleveland Clinic Cardiovascular Coordinating Center. Cleveland, OH (February 14, 2002).

6. "Risk stratification in coronary artery disease." Cleveland Clinic Foundation, *An Intensive Review of Cardiology*. Cleveland, OH (September 27, 2002).
7. "Carotid Stenting: Is It Ready For Prime Time?" University of Pennsylvania, Division of Cardiovascular Medicine Grand Rounds (October 9, 2003).
8. "Endovascular Therapy For Carotid Artery Stenosis: Has The Paradigm Shifted" University of Pennsylvania, Department of Medicine Grand Rounds (October 28, 2003).
9. "Endovascular Therapy For Peripheral Arterial Disease." Cardiovascular Medicine Fellows Summer Lecture Series. Hospital of the University of Pennsylvania. Philadelphia, PA (July 20, 2004).
10. "Cutting Edge Endovascular Therapy for Peripheral Arterial Disease." University of Pennsylvania Health System Media Day. Philadelphia, PA (October 12, 2004).
11. "Carotid Stenting: Selecting Cases and Techniques." Interventional Cardiovascular Medicine Lecture Series. Hospital of the University of Pennsylvania. Philadelphia, PA (October 26, 2004).
12. "Percutaneous Carotid Intervention Trials." Penn Update on Percutaneous Carotid and Brachiocephalic Interventions. Philadelphia, PA (October 29, 2004).
13. "Carotid Stenting: Neck and Neck with Endarterectomy?" Philadelphia Veterans Administration Medical Center Medicine Grand Rounds/Internal Medicine Update Series 2004-2005. Philadelphia, PA (November 17, 2004).
14. "Latest Advances in Endovascular Therapy for Peripheral Arterial Disease." Philadelphia Veterans Administration Medical Center Primary Care Conference. Philadelphia, PA (November 19, 2004).
15. "Peripheral Arterial Disease." Diabetes Support Group, Rodebaugh Diabetes Center, Hospital of the University of Pennsylvania. Philadelphia, PA (February 2, 2005).
16. "Carotid Stenting: Where Are We Headed?" Department of Medicine Grand Rounds. St. Joseph Mercy Hospital. Ann Arbor, MI (August 10, 2005).
17. "Carotid Stenting: Neck & Neck With Endarterectomy?" Department of Medicine Grand Rounds. St. Mary Mercy Hospital. Livonia, MI (September 7, 2005).
18. "Peripheral Arterial Disease" St. Joseph Mercy Hospital Department of Medicine Resident Noon Lecture Series. Ann Arbor, MI (January 23, 2006).
19. "Carotid Stenting: Neck & Neck with Endarterectomy?" St. Joseph Mercy Hospital Family Practice Grand Rounds. Ann Arbor, MI (January 25, 2006).
20. "Carotid Stenting: Trials and Tribulations" Chelsea Community Hospital Medicine Service Grand Rounds. Chelsea, MI (February 13, 2006).

21. “Carotid Stenting: Neck & Neck With Endarterectomy?” New Directions in Cardiovascular Disease. Jackson, MI (March 25, 2006).
22. “Peripheral Arterial Disease.” Leg Pain: Could It Be My Circulation? Michigan Heart & Vascular Institute Peripheral Vascular Disease Conference. Ann Arbor, MI (June 10, 2006).
23. “Carotid and Peripheral Stenting.” Michigan Heart & Vascular Institute Echocardiography Conference. Ann Arbor, MI (June 14, 2006).
24. “Prevention & Management of Vascular Complications.” St. Joseph Mercy Hospital Nursing Inservice. Ann Arbor, MI (November 8, 2006).
25. “Revascularization for the Prevention and Treatment of Stroke.” Healing the Stroke Patient: A Multidisciplinary Conference. St. Joseph Mercy Hospital. Ann Arbor, MI (April 26, 2007).
26. “Carotid Stenting: Heading Into A New Frontier” St. Mary Mercy Hospital Symposium on Technology and Innovation. Livonia, MI (May 19, 2007).
27. “Carotid Stenting: A Review for Primary Care Physicians” Livonia, MI (May 22, 2007).
28. “Lp-PLA2 – An Emerging Risk Factor For Atherosclerotic Vascular Disease.” St. Joseph Mercy Hospital Department of Medicine Grand Rounds. Ann Arbor, MI (October 31, 2007).
29. “Lower Extremity Endovascular Intervention for Claudication and Critical Limb Ischemia.” St. Joseph Mercy Hospital Podiatry Grand Rounds. Ann Arbor, MI (February 5, 2008).
30. “Percutaneous Treatment for Peripheral Vascular Disease.” Michigan Heart & Vascular Institute’s 9<sup>th</sup> Annual Cardiovascular Seminar -.Cardiovascular Technology: Latest and Greatest. Ann Arbor, MI (February 5, 2008).
31. “The Role of Statins in Peripheral Vascular Disease.” New Insights in Vascular Technology. Michigan Heart & Vascular Institute. Ann Arbor, MI (May 10, 2008).
32. “Carotid Stenting Nursing Inservice.” St. Mary Mercy Hospital. Livonia, MI (June 27, 2008).
33. “Carotid stenting vs. endarterectomy: Let the games begin!” Michigan Heart & Vascular Institute New Insights in Vascular Technology. Ann Arbor, MI (May 9, 2009).
34. “Carotid Stenting vs. Endarterectomy: And the Winner is...” Department of Medicine Grand Rounds. St. Joseph Mercy Hospital. Ann Arbor, MI (March 24, 2010).
35. “Percutaneous Treatment of Peripheral Vascular Disease.” St. Joseph Mercy Hospital Internal Medicine Residency Program Conference. Ann Arbor, MI (March 30, 2010).

36. "Peripheral Arterial Disease: Current Status and Future Directions." St. Joseph Mercy Hospital Internal Medicine Residency Program Conference. Ann Arbor, MI (November 4, 2010).
37. "Transcatheter Aortic Valve Implantation." Michigan Heart & Vascular Institute 12<sup>th</sup> Annual Cardiovascular Seminar. Ann Arbor, MI (February 3, 2011).
38. "SYMPPLICITY HTN-3: Will catheter-based renal sympathetic denervation replace pharmacotherapy for treatment of HTN?" St. Joseph Mercy Hospital Family Medicine/Internal Medicine Grand Rounds. Ann Arbor, MI (February 29, 2012).
39. "Overview of PAD." Department of Internal Medicine Noon Conference. St. Joseph Mercy Hospital, Ann Arbor, MI (July 5, 2012)
40. "The ISCHEMIA Trial. St. Joseph Mercy Hospital Cardiovascular Grand Rounds. Ann Arbor, MI (October 16, 2012).
41. "Using Risk Scores for Cardiac Catheterization and PCI." St. Joseph Mercy Hospital Cardiovascular Grand Rounds. Ann Arbor, MI (October 28, 2014).
42. "CREST 2 Trial Update." Neurology Section Meeting. St. Joseph Mercy Hospital. Ann Arbor, MI (3/2/15).
43. "Medicine, Surgery or Stents for Asymptomatic Carotid Stenosis: A Multidisciplinary Debate." Brown Department of Neurology Grand Rounds. Rhode Island Hospital. Providence, RI (11/23/16)
44. "Contemporary Management of Carotid Stenosis." Cardiovascular Institute Grand Rounds. Rhode Island Hospital. Providence, RI (2/3/17)
45. "Device Therapies for HTN" Newport Hospital Grand Rounds. Newport, RI (6/21/18).
46. "Device Therapy for Hypertension: New Trials, New Opportunities" Cardiovascular Institute Grand Rounds. Rhode Island Hospital. Providence, RI (6/22/18).
47. "Carotid Artery Disease." Cardiovascular Advanced Practice Provider Lecture Series. Rhode Island Hospital. Providenc, RI (8/22/18).
48. "Device Therapies for HTN: Are Pills Passé?" Brown Department of Medicine Grand Rounds. Providence, RI (11/27/18)

## GRANTS

### Present and Active

2018 – present      Role: Co-investigator (PI Lisa Merck, MD). ACCESS trial (Access to the Cardiac Cath Lab in Patients Without STEMI Resuscitated from Out-of-hospital VT/VF Cardiac Arrest). Rhode Island Hospital. Providence, RI.



## Past

- 1988 Role: Investigator (PI: Warren Lockette, MD, PhD). American Heart Association of Michigan Medical Student Research Fellowship. University of Michigan/Wayne State University, Detroit, Michigan. The effects of select vasoactive agents on intracellular pH and calcium concentration in vascular smooth muscle.
- 2000 - 2001 Role: PI. CardioFellows Foundation Research Grant. Cleveland Clinic Foundation, Cleveland, OH. Coronary artery acoustic imaging: A new, non-invasive method for the detection of physiologically significant coronary stenoses. Total award: \$35,000.
- 2006 - 2007 Role: PI. Bayer Healthcare Investigator Initiated Research Grant. St. Joseph Mercy Hospital, Ann Arbor, MI. Association between aspirin dose, all-cause mortality and bleeding in the BRAVO trial. Total award: \$50,300.
- 2011 - 2012 Role: Clinical mentor. 2011 National Collegiate Inventors and Innovators Alliance – BMEidea (Biomedical Engineering Innovation, Design and Entrepreneurship Award). University of Michigan, Biomedical Engineering Department, Ann Arbor, MI. Magneto: Magnetic Induction Internal Bleed Detector. Total award: \$10,000.
- 2011 - 2014 Role: PI. Sage Foundation. St. Joseph Mercy Hospital, Ann Arbor, MI. Development of a risk score-based approach to identify patients in whom same day discharge is feasible and safe following percutaneous coronary intervention. Total award: \$50,000.
- 2012 - present Role: Consultant, Clinician Expert Panel (PI: Kim Smolderen, PhD). St. Joseph Mercy Hospital, Ann Arbor, MI. Patient-Centered Outcomes Research Institute (PCORI, 1 IP2 PI000753-01). Patient-centered Outcomes Recovery from Treating PAD: Investigating Trajectories (PORTRAIT). Total award: \$639,498.
- 2013 - 2016 Role: Co-Investigator (PI: Kim Smolderen, PhD). St. Joseph Mercy Hospital, Ann Arbor, MI. Patient-Centered Outcomes Research Institute (PCORI, CE-1304-6677). Patient-centered Outcomes Recovery from Treating peripheral Arterial disease: Investigating Trajectories (PORTRAIT) - Phase II. Total award: \$1,829,382 (St. Joseph Mercy Hospital \$87,975).
- 2014 - 2016 Role: Principal Investigator. Blue Cross Blue Shield of Michigan Foundation (HSR-14-1479; clinicaltrials.gov ID NCT02207270). St. Joseph Mercy Hospital, Ann Arbor, MI. Study Of Costs Realized After percutaneous coronary intervenTion Employing Same day discharge (SOCRATES). Total award: \$107,740.

Multicenter Clinical Trials (referenced where results have been published)

1. Site Principal Investigator, REVERSAL trial brachial reactivity substudy. Cleveland Clinic Foundation, Cleveland, OH (1999-2001). Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. *JAMA*. 2004;291:1071-1080.
2. Site Principal Investigator, CABERNET trial. Hospital of the University of Pennsylvania, Philadelphia, PA (2003-2004). Hopkins LN, Myla S, Grube E, Wehman JC, Levy EI, Bersin RM, Joye JD, Alocco DJ, Kelley L, Baim DS. Carotid artery revascularization in high surgical risk patients with the NexStent and the Filterwire EX/EZ: 1-year results in the CABERNET trial. *Catheter Cardiovasc Interv*. 2008;71:950-960.
3. Site Principal Investigator, PERISCOPE trial. Hospital of the University of Pennsylvania, Philadelphia, PA (2003-2005). Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larocheiliere R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. *Jama*. 2008;299:1561-1573.
4. Site Principal Investigator, EXACT trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2005-2007). Gray WA, Chaturvedi S, Verta P. Thirty-day outcomes for carotid artery stenting in 6320 patients from 2 prospective, multicenter, high-surgical-risk registries. *Circ Cardiovasc Interv*. 2009;2:159-166.
5. Site Principal Investigator, CREST trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2005-2008). Brott TG, Hobson RW, 2nd, Howard G, Roubin GS, Clark WM, Brooks W, Mackey A, Hill MD, Leimgruber PP, Sheffet AJ, Howard VJ, Moore WS, Voeks JH, Hopkins LN, Cutlip DE, Cohen DJ, Popma JJ, Ferguson RD, Cohen SN, Blackshear JL, Silver FL, Mohr JP, Lal BK, Meschia JF. Stenting versus endarterectomy for treatment of carotid-artery stenosis. *N Engl J Med*. 2010;363:11-23.
6. Site Principal Investigator, CAPTURE-2 trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2006-2007). Matsumura JS, Gray W, Chaturvedi S, Gao X, Cheng J, Verta P. CAPTURE 2 risk-adjusted stroke outcome benchmarks for carotid artery stenting with distal embolic protection. *J Vasc Surg*. 2010;52:576-583, 583 e571-583 e572.
7. Site Principal Investigator, PROTECT trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2007-2008). Cremonesi A. The SPIDER Embolic Protection Device performance evaluation in the carotid artery during percutaneous transluminal angioplasty and or stenting. *J Invasive Cardiol*. 2005;17:463-467.
8. Site Principal Investigator, SONOMA trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2007-2008). *Study terminated after voluntary device recall*.

9. Site Principal Investigator, CORAL trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2006-2013). Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ, Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI, Rundback JH, Massaro JM, D'Agostino RB, Sr., Dworkin LD. Stenting and medical therapy for atherosclerotic renal-artery stenosis. *N Engl J Med.* 2014;370:13-22.
10. Site Principal Investigator, SAPPHIRE WW trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2007-2014). Massop D, Dave R, Metzger C, Bachinsky W, Solis M, Shah R, Schultz G, Schreiber T, Ashchi M, Hibbard R. Stenting and angioplasty with protection in patients at high-risk for endarterectomy: SAPPHIRE Worldwide Registry first 2,001 patients. *Catheter Cardiovasc Interv.* 2009;73:129-136.
11. Site Principal Investigator, CHOICE trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2007-2012); St. Mary Mercy Hospital, Livonia, MI (2007-2010). Shishehbor MH, Venkatachalam S, Gray WA, Metzger C, Lal BK, Peng L, Omran HL, Blackstone EH. Experience and outcomes with carotid artery stenting: an analysis of the CHOICE study (Carotid Stenting for High Surgical-Risk Patients; Evaluating Outcomes Through the Collection of Clinical Evidence). *JACC Cardiovasc Interv.* 2014;7:1307-1317.
12. Site Principal Investigator, GRAVITAS trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2008-2009). Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA.* 2011;305:1097-1105.
13. Site Principal Investigator, DURABILITY II trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2009-2012). Matsumura JS, Yamanouchi D, Goldstein JA, Pollock CW, Bosiers M, Schultz GA, Scheinert D, Rocha-Singh KJ. The United States Study for Evaluating Endovascular Treatments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By using the Protege Everflex Nitinol Stent System II (DURABILITY II). *J Vasc Surg.* 2013;58:73-83 e71.
14. Site Principal Investigator, TIMI 52 – SOLID trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2010-2014). O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP, Steen DL. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. *JAMA.* 2014;312:1006-1015.
15. Site Principal Investigator, CONFIRM III OUTFLOW registry. St. Joseph Mercy Hospital, Ann Arbor, MI (2011). Lee M. Pooled Analysis of the CONFIRM Registries: Outcomes in Elderly Patients. *J Am Coll Cardiol* 2013(62:18\_S1):B162.
16. Site Principal Investigator, OSPREY trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2011-2013). Ohki T, Angle JF, Hiroyoshi Y, Jaff M. Effectiveness of the Misago stent for the treatment of superficial femoral artery disease: 12-month Results of the First Japan and the United States Collaboration. *J Am Coll Cardiol* 2014(11\_S).

17. Site Principal Investigator, BIOFLEX-I trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2011-2013). Burkett MW, Brodmann M, Jaff MR. Clinical Outcomes of the BIOFLEX-I Study: Utilization of Self Expanding Stents in the Iliac Arteries. *J Am Coll Cardiol Intv* 2015;8(2\_S)S32-S33.
18. Site Principal Investigator, LEVANT-2 trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2011-2014). Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Muller-Hulsbeck S, Nehler MR, Benenati JF, Scheinert D. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. *N Engl J Med*. 2015.
19. Site Principal Investigator, SYMPLICITY HTN 3 trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2011-2015). Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. A controlled trial of renal denervation for resistant hypertension. *N Engl J Med*. 2014;370:1393-1401.
20. Site Principal Investigator, ABSORB III trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2011 – 2015). Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW and Investigators AI. 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial. *J Am Coll Cardiol*. 2017;70:2852-2862.
21. Site Principal Investigator, BEST-CLI trial. St. Joseph Mercy Hospital, Ann Arbor, MI; St. Mary Mercy Hospital, Livonia, MI (2012 – 2015).
22. Site Principal Investigator, ABSORB IV trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2014 – 2015). Stone GW, Ellis SG, Gori T, Metzger DC, Stein B, Erickson M, Torzewski J, Williams J, Jr., Lawson W, Broderick TM, Kabour A, Piegari G, Cavendish J, Bertolet B, Choi JW, Marx SO, Genereux P, Kereiakes DJ and Investigators AI. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. *Lancet*. 2018.
23. Site Principal Investigator, SYMPLICITY HTN-4 trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2014).
24. Site Principal Investigator, EnligHTN IV trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2014).
25. Site Principal Investigator, CREST-2 trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2014 – 2015).
26. Site Principal Investigator, Bionics trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2015). Kandzari DE, Smits PC, Love MP, Ben-Yehuda O, Banai S, Robinson SD, Jonas M, Kornowski R, Bagur R, Iniguez A, Danenberg H, Feldman R, Jauhar R, Chandna H, Parikh M, Perlman GY, Balcells M, Markham P, Ozan MO, Genereux P, Edelman ER, Leon MB and Stone GW. Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting

Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis). *Circulation*. 2017;136:1304-1314.

27. Site Principal Investigator, CALM-FIM trial. St. Joseph Mercy Hospital, Ann Arbor, MI (2015).
28. Site Sub Investigator, BEST-CLI trial. The Miriam Hospital. Providence, RI (2015 – present).
29. Site Sub Investigator, Viabahn ISR trial. The Miriam Hospital. Providence, RI (2015 – present).
30. Site Sub Investigator, Lutonix ISR trial. The Miriam Hospital. Providence, RI (2015 – present).
31. Site Sub Investigator, Scaffold trial. The Miriam Hospital. Providence, RI (2015 – 2016).
32. Site Principal Investigator, CREST-2 trial. The Miriam Hospital. Providence, RI (2016 – present).
33. Site Principal Investigator, ROADSTER-2 trial. Rhode Island Hospital. Providence, RI (2016 – 2017).
34. Site Principal Investigator, CREST-2 Registry (C2R). Rhode Island and The Miriam Hospitals. Providence, RI (2016 – present).
35. Site Principal Investigator, Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention (TWILIGHT). Rhode Island and The Miriam Hospitals. Providence, RI (2016 – present).
36. Site Principal Investigator, A prospective, randomized, adaptive, double-blind, sham controlled, multicenter study to evaluate the ROX Coupler in subjects with hypertension. Rhode Island Hospital. Providence, RI (2018 – present)
37. Site Principal Investigator, SPYRAL-HTN OFF MED trial. The Miriam Hospital. Providence, RI (2018 – present)
38. Site Principal Investigator, ECCLIPSE trial. Rhode Island Hospital. Providence, RI (2018 - present).

#### UNIVERSITY TEACHING ROLES

1. “On Becoming an Interventional Cardiologist.” William Pepper Medical Society, University of Pennsylvania School of Medicine. Philadelphia, PA (December 6, 2004).
2. University of Michigan Department of Internal Medicine HOIII Career Development Retreat. Panel member. Ann Arbor, MI (September 18, 2008).

3. Guest lecturer, Biomedical Engineering 599. “Ostial and bifurcation disease: The Achilles heel of interventional vascular medicine.” Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI (2009).
4. Project Facilitator, Biomedical Engineering 450. Supervised 6 undergraduate students on development of a novel device using electrical impedance for early detection of femoral artery bleeding post-catheterization. Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI (2010).
5. Project Advisor, Biomedical Engineering 599. Supervised 5 undergraduate students on development of a novel device using magnetic induction for early detection of femoral artery bleeding post-catheterization. Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI (2010-2011).
6. “Iliac Artery Intervention.” Brown Interventional Cardiology Fellowship Lecture Series. Rhode Island Hospital. Providence, RI (10/28/15)
7. “Renal Artery Intervention.” Brown Interventional Cardiology Fellowship Lecture Series. Rhode Island Hospital. Providence, RI (1/6/16)
8. “Renal Artery Intervention.” Brown Interventional Cardiology Fellowship Lecture Series. Rhode Island Hospital. Providence, RI (8/17/16)
9. Small Group Facilitator, Med Ed-Biol3662 (Integrated Medical Sciences III – Cardiovascular). Warren Alpert Medical School of Brown University (2016-2019)
10. Lecturer, Biomedical Engineering Capstone Design (ENGN 1930L). “Cardiac Catheterization: Challenges and Opportunities.” Brown University. Providence, RI (9/12/16).
11. “Quality Improvement in the Cardiac Cath Lab.” Brown Interventional Cardiology Fellowship Lecture Series. Rhode Island Hospital. Providence, RI (9/14/16)
12. “Approach to the Patient with PAD.” Brown Department of Medicine Resident Noon Conference. Rhode Island Hospital. Providence, RI (10/16/17).
13. “Cardiovascular Research.” Brown Department of Medicine Resident Noon Conference. Rhode Island Hospital. Providence, RI (11/6/17).
14. “Cardiac Cath Lab Quality.” Brown Interventional Cardiology Fellowship Lecture Series. Rhode Island Hospital. Providence, RI (10/4/17)
15. “Evaluation and Treatment of Renal Artery Disease.” Brown University Internal Medicine Residency Noon Conference. Rhode Island Hospital. Providence, RI (1/31/18)
16. “Evaluation and Treatment of Renal Artery Disease.” Brown University Internal Medicine Residency Noon Conference. The Miriam Hospital. Providence, RI (2/7/18)

17. “Lower Extremity Peripheral Artery Disease Guidelines and Appropriate Use Criteria for Lower Extremity Peripheral Vascular Intervention.” Brown Interventional Cardiology Fellowship Lecture Series. Rhode Island Hospital. Providence, RI (3/27/19).
18. “Quality Improvement in the Cath Lab.” Brown Interventional Cardiology Fellowship Lecture Series. Rhode Island Hospital. Providence, RI (8/7/19).

#### HOSPITAL TEACHING ROLES

1. Attending Physician, Medical Teaching Service, Department of Internal Medicine, St. Joseph Mercy Hospital, Ann Arbor, MI (1997-1998).
2. Attending Physician, Department of Internal Medicine, Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Philadelphia, PA (2003-2005).
3. Attending Physician, Department of Internal Medicine, Division of Cardiovascular Medicine, St. Joseph Mercy Hospital, Ann Arbor, MI (2005-present).
4. Attending Physician, Department of Internal Medicine, Division of Cardiovascular Medicine, St. Mary Mercy Hospital, Livonia, MI (2005-present).
5. Attending Physician, Department of Internal Medicine, Division of Cardiovascular Medicine, Allegiance Hospital. Jackson, MI (2014-present).
6. Attending Physician, Department of Internal Medicine, Division of Cardiovascular Medicine, Rhode Island Hospital. Providence, RI (2015 – present)
7. Attending Physician, Department of Internal Medicine, Division of Cardiovascular Medicine, The Miriam Hospital. Providence, RI (2015 – present)